References
References 1-50
Ref. 1. American Association for Cancer Research. AACR Cancer Progress Report 2023. Accessed: Feb 29, 2024. Available from: https://cancerprogressreport.aacr.org/wp-content/uploads/sites/2/2023/10/AACR_CPR_2023_102423.pdf
Ref. 2. American Cancer Society. Cancer Facts and Figures 2024. Accessed: July 10, 2024. Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2024/2024-cancer-facts-and-figures-acs.pdf
Ref. 3. NCI Surveillance, Epidemiology, and End Results Program. NCI SEER*Explorer. Accessed: March 17, 2024. Available from: https://seer.cancer.gov/statistics-network/explorer/application.html
Ref. 4. Siegel RL, et al. (2024) CA Cancer J Clin, 74: 12. DOI: 10.3322/caac.21820.
Ref. 5. de Koning HJ, et al. (2020) N Engl J Med, 382: 503. DOI: 10.1056/NEJMoa1911793.
Ref. 6. Robertson SE, et al. (2024) JAMA Netw Open, 7: e2346295. DOI: 10.1001/jamanetworkopen.2023.46295.
Ref. 7. Howlader N, et al. (2023) Cancer Epidemiol Biomarkers Prev, 32: 744. Available from: https://doi.org/10.1158/1055-9965.EPI-22-1171
Ref. 8. Choueiri TK, et al. (2024) N Engl J Med, 390: 1359. DOI: 10.1056/NEJMoa2312695.
Ref. 9. Miller KD, et al. (2022) CA Cancer J Clin, 72: 409. DOI: 10.3322/caac.21731.
Ref. 10. Gallicchio L, et al. (2022) J Natl Cancer Inst, 114: 1476. DOI: 10.1093/jnci/djac158.
Ref. 11. Centers for Disease Control and Prevention. Declines in Cancer Death Rates Among Youth: United States, 2001–2021. Accessed: July 5, 2024. Available from: https://stacks.cdc.gov/view/cdc/134499
Ref. 12. Keegan THM, et al. (2024) J Clin Oncol, 42: 630. DOI: 10.1200/JCO.23.01367.
Ref. 13. Hoppmann AL, et al. (2023) Cancer Epidemiol Biomarkers Prev, 32: 380. Available from: https://doi.org/10.1158/1055-9965.EPI-22-0353
Ref. 14. Price M, et al. (2024) Neuro Oncol, 26: iii1. DOI: 10.1093/neuonc/noae047.
Ref. 15. Koh B, et al. (2023) JAMA Netw Open, 6: e2328171. DOI: 10.1001/jamanetworkopen.2023.28171.
Ref. 16. Siegel RL, et al. (2023) CA Cancer J Clin, 73: 233. DOI: 10.3322/caac.21772.
Ref. 17. Giannakis M, et al. (2023) Science, 379: 1088. DOI: 10.1126/science.ade7114.
Ref. 18. Sinicrope FA (2022) N Engl J Med, 386: 1547. DOI: 10.1056/NEJMra2200869.
Ref. 19. Francoeur AA, et al. (2022) Int J Gynecol Cancer, 32: 1115. DOI: 10.1136/ijgc-2022-003728.
Ref. 20. Shahmoradi Z, et al. (2022) JAMA, 328: 2267. DOI: 10.1001/jama.2022.17806.
Ref. 21. Rubin JB, et al. (2024) J Clin Invest, 134. DOI: 10.1172/JCI180071.
Ref. 22. Yang W, et al. (2024) Biol Sex Differ, 15: 35. DOI: 10.1186/s13293-024-00607-1.
Ref. 23. Rubin JB (2022) Trends Cancer, 8: 303. DOI: 10.1016/j.trecan.2022.01.013.
Ref. 24. American Association for Cancer Research. AACR Report on the Impact of COVID-19 on Cancer Research and Patient Care. Accessed: June 30, 2022. Available from: https://www.aacr.org/professionals/research/aacr-covid-19-and-cancer-report-2022/
Ref. 25. Berrian J, et al. (2023) Cancer Med, 12: 7381. DOI: 10.1002/cam4.5439.
Ref. 26. Zhao J, et al. (2023) JCO Oncol Pract, 19: 501. DOI: 10.1200/OP.22.00522.
Ref. 27. Llanos AAM, et al. (2023) JAMA Netw Open, 6: e2251165. DOI: 10.1001/jamanetworkopen.2022.51165.
Ref. 28. Han X, et al. (2023) Lancet Oncol, 24: 855. DOI: 10.1016/S1470-2045(23)00293-0.
Ref. 29. American Association for Cancer Research. AACR Cancer Disparities Progress Report 2024. Accessed: June 14, 2024. Available from: https://cancerprogressreport.aacr.org/wp-content/uploads/sites/2/2024/05/AACR_CDPR__2024.pdf
Ref. 30. American Lung Association. State of the Air 2023 Report. Accessed: March 17, 2024. Available from: https://www.lung.org/getmedia/338b0c3c-6bf8-480f-9e6e-b93868c6c476/SOTA-2023.pdf
Ref. 31. Melkonian SC, et al. (2024) Cancer Epidemiol Biomarkers Prev: OF1. Available from: https://doi.org/10.1158/1055-9965.EPI-24-0179
Ref. 32. Semprini J, et al. (2024) Cancer Epidemiol Biomarkers Prev: OF1. Available from: https://doi.org/10.1158/1055-9965.EPI-24-0072
Ref. 33. Tundealao S, et al. (2023) Cancer Causes Control, 34: 1027. DOI: 10.1007/s10552-023-01749-0.
Ref. 34. Kim HW, et al. (2020) Clin Transl Gastroenterol, 11: e00242. DOI: 10.14309/ctg.0000000000000242.
Ref. 35. Moss JL, et al. (2022) J Natl Cancer Inst, 114: 829. DOI: 10.1093/jnci/djac038.
Ref. 36. Haverkamp D, et al. (2023) Int J Circumpolar Health, 82: 2184749. DOI: 10.1080/22423982.2023.2184749.
Ref. 37. Zhu DT, et al. (2024) J Racial Ethn Health Disparities, 00: 1. DOI: 10.1007/s40615-024-02067-0.
Ref. 38. Fowler ME, et al. (2023) J Geriatr Oncol, 14: 101505. DOI: 10.1016/j.jgo.2023.101505.
Ref. 39. Warnecke RB, et al. (2008) Am J Public Health, 98: 1608. DOI: 10.2105/AJPH.2006.102525.
Ref. 40. Asare M, et al. (2017) Oncol Nurs Forum, 44: 20. DOI: 10.1188/17.ONF.20-23.
Ref. 41. Islami F, et al. (2023) CA Cancer J Clin. DOI: 10.3322/caac.21812.
Ref. 42. Zhao J, et al. (2022) CA Cancer J Clin, 72: 542. DOI: 10.3322/caac.21732.
Ref. 43. Chen SY, et al. (2023) Surgery, 174: 1323. DOI: 10.1016/j.surg.2023.09.005.
Ref. 44. Bassiri A, et al. (2024) J Surg Res, 293: 248. DOI: 10.1016/j.jss.2023.09.013.
Ref. 45. Samuel D, et al. (2023) Gynecol Oncol, 174: 1. DOI: 10.1016/j.ygyno.2023.04.017.
Ref. 46. World Health Organization. Global Cancer Observatory: Cancer Today (version 1.1). Lyon, France: International Agency for Research on Cancer. Accessed: August 2, 2024. Available from: https://gco.iarc.who.int/today/
Ref. 47. United States Census Bureau. 2023 Population Projections for the Nation by Age, Sex, Race, Hispanic Origin and Nativity. Accessed: July 10, 2024. Available from: https://www.census.gov/newsroom/press-kits/2023/population-projections.html
Ref. 48. Islami F, et al. (2024) CA Cancer J Clin. DOI: 10.3322/caac.21858.
Ref. 49. Cornelius ME, et al. (2023) MMWR Morb Mortal Wkly Rep, 72: 475. DOI: 10.15585/mmwr.mm7218a1.
Ref. 50. Siegel DA, et al. (2021) JAMA Oncol, 7: 302. DOI: 10.1001/jamaoncol.2020.6362.
References 51-100
Ref. 51. Pelosof L, et al. (2017) J Natl Cancer Inst, 109: djw295. DOI: 10.1093/jnci/djw295.
Ref. 52. Sakoda LC, et al. (2023) Chest, 164: 785. DOI: 10.1016/j.chest.2023.03.016.
Ref. 53. Jemal A, et al. (2023) JAMA Oncol, 9: 1727. DOI: 10.1001/jamaoncol.2023.4415.
Ref. 54. Rosenberg PS, et al. (2024) JAMA Netw Open, 7: e2415731. DOI: 10.1001/jamanetworkopen.2024.15731.
Ref. 55. Bray F, et al. (2024) CA Cancer J Clin, 74: 229. DOI: 10.3322/caac.21834.
Ref. 56. World Health Organization. Breast Cancer. Accessed: August 7, 2024. Available from: https://www.who.int/news-room/fact-sheets/detail/breast-cancer
Ref. 57. Benitez Fuentes JD, et al. (2024) JAMA Oncol, 10: 71. DOI: 10.1001/jamaoncol.2023.4837.
Ref. 58. James ND, et al. (2024) Lancet, 403: 1683. DOI: 10.1016/S0140-6736(24)00651-2.
Ref. 59. Frick C, et al. (2023) Lancet Glob Health, 11: e1700. DOI: 10.1016/S2214-109X(23)00406-0.
Ref. 60. Ugai T, et al. (2022) Nat Rev Clin Oncol, 19: 656. DOI: 10.1038/s41571-022-00672-8.
Ref. 61. Zhao J, et al. (2023) BMJ Oncology, 2: e000049. DOI: 10.1136/bmjonc-2023-000049.
Ref. 62. McIntosh SA, et al. (2023) Lancet Oncol, 24: 636. DOI: 10.1016/S1470-2045(23)00182-1.
Ref. 63. Chen S, et al. (2023) JAMA Oncol, 9: 465. DOI: 10.1001/jamaoncol.2022.7826.
Ref. 64. Parsons SK, et al. (2023) J Clin Oncol, 41: 3260. DOI: 10.1200/JCO.22.01985.
Ref. 65. Kuehn BM (2021) JAMA, 326: 2251. DOI: 10.1001/jama.2021.21119.
Ref. 66. Nayak RK, et al. (2021) JAMA Intern Med, 181: 1522. DOI: 10.1001/jamainternmed.2021.3720.
Ref. 67. Galkina Cleary E, et al. (2023) JAMA Health Forum, 4: e230511. DOI: 10.1001/jamahealthforum.2023.0511.
Ref. 68. Unger JM, et al. (2023) J Clin Oncol, 41: 2020. DOI: 10.1200/Jco.22.01826.
Ref. 69. Shiels MS, et al. (2023) Cancer Discov, 13: 1084. Available from: https://doi.org/10.1158/2159-8290.CD-23-0208
Ref. 70. Bertagnolli MM, et al. (2023) Cancer Discov, 13: 1049. Available from: https://doi.org/10.1158/2159-8290.CD-23-0344
Ref. 71. Hanahan D (2022) Cancer Discov, 12: 31. Available from: https://doi.org/10.1158/2159-8290.CD-21-1059
Ref. 72. National Institutes of Health. The Office of Budget. National Institutes of Health FY 2003 – FY 2023 Distribution of Budget Authority Percentages for Basic and Applied Research. Accessed: June 26, 2024. Available from: https://officeofbudget.od.nih.gov/pdfs/FY25/spending_hist/Basic%20and%20Applied%20FY%202003%20-%20FY%202023%20(V).pdf
Ref. 73. American Association for Cancer Research. AACR Cancer Progress Report 2021. Accessed: June 30, 2023. Available from: https://cancerprogressreport.aacr.org/wp-content/uploads/sites/2/2021/10/AACR_CPR_2021.pdf
Ref. 74. Fischer EH, et al. (1955) J Biol Chem, 216: 121.
Ref. 75. Burnett G, et al. (1954) J Biol Chem, 211: 969.
Ref. 76. Singh V, et al. (2017) Protein J, 36: 1. DOI: 10.1007/s10930-017-9696-z.
Ref. 77. Ubersax JA, et al. (2007) Nat Rev Mol Cell Biol, 8: 530. DOI: 10.1038/nrm2203.
Ref. 78. Turdo A, et al. (2021) Front Cell Dev Biol, 9: 690306. DOI: 10.3389/fcell.2021.690306.
Ref. 79. Manning G, et al. (2002) Science, 298: 1912. DOI: 10.1126/science.1075762.
Ref. 80. Bhullar KS, et al. (2018) Mol Cancer, 17: 48. DOI: 10.1186/s12943-018-0804-2.
Ref. 81. Cohen P (2002) Nat Rev Drug Discov, 1: 309. DOI: 10.1038/nrd773.
Ref. 82. Roskoski R, Jr. (2024) Pharmacol Res, 200: 107059. DOI: 10.1016/j.phrs.2024.107059.
Ref. 83. Marin-Acevedo JA, et al. (2021) J Hematol Oncol, 14: 45. DOI: 10.1186/s13045-021-01056-8.
Ref. 84. American Association for Cancer Research. AACR Cancer Progress Report 2022. Accessed: July 5, 2023. Available from: https://cancerprogressreport.aacr.org/wp-content/uploads/sites/2/2022/09/AACR_CPR_2022.pdf
Ref. 85. Sorscher S, et al. (2023) JCO Precis Oncol, 7: e2300190. DOI: 10.1200/PO.23.00190.
Ref. 86. Houlahan KE, et al. (2024) Science, 384: eadh8697. DOI: 10.1126/science.adh8697.
Ref. 87. National Cancer Institute. Targeted Therapy Drug List by Cancer Type. Accessed: July 5, 2023. Available from: https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies/approved-drug-list
Ref. 88. Bradley RK, et al. (2023) Nat Rev Cancer, 23: 135. DOI: 10.1038/s41568-022-00541-7.
Ref. 89. Stanley RF, et al. (2022) Nature Cancer, 3: 536. DOI: 10.1038/s43018-022-00384-z.
Ref. 90. Yan H, et al. (2021) Essays Biochem, 65: 625. DOI: 10.1042/EBC20200032.
Ref. 91. Ambros V (2004) Nature, 431: 350. DOI: 10.1038/nature02871.
Ref. 92. Statello L, et al. (2021) Nat Rev Mol Cell Biol, 22: 96. DOI: 10.1038/s41580-020-00315-9.
Ref. 93. Hayes J, et al. (2014) Trends Mol Med, 20: 460. DOI: 10.1016/j.molmed.2014.06.005.
Ref. 94. Huarte M (2015) Nat Med, 21: 1253. DOI: 10.1038/nm.3981.
Ref. 95. Liu T, et al. (2019) J Cell Physiol, 234: 5496. DOI: 10.1002/jcp.27342.
Ref. 96. Hakami MA, et al. (2024) Pathol Res Pract, 253: 154957. DOI: 10.1016/j.prp.2023.154957.
Ref. 97. Cantile M, et al. (2024) Front Mol Biosci, 11: 1414651. DOI: 10.3389/fmolb.2024.1414651.
Ref. 98. Martinez-Ruiz C, et al. (2023) Nature, 616: 543. DOI: 10.1038/s41586-023-05706-4.
Ref. 99. Wild SA, et al. (2022) Elife, 11: e80981. DOI: 10.7554/eLife.80981.
Ref. 100. Dressler FF, et al. (2024) Nat Commun, 15: 4513. DOI: 10.1038/s41467-024-48096-5.
References 101-150
Ref. 101. Uversky VN. Posttranslational Modification. Academic Press: Elsvier; 2013.
Ref. 102. Wang H, et al. (2023) Cancer Gene Ther, 30: 529. DOI: 10.1038/s41417-022-00464-3.
Ref. 103. Geffen Y, et al. (2023) Cell, 186: 3945. DOI: 10.1016/j.cell.2023.07.013.
Ref. 104. Lu Y, et al. (2020) Mol Cancer, 19: 79. DOI: 10.1186/s12943-020-01197-3.
Ref. 105. Yu X, et al. (2024) Cell Death Discov, 10: 28. DOI: 10.1038/s41420-024-01803-z.
Ref. 106. Cheng MW, et al. (2023) Commun Biol, 6: 1138. DOI: 10.1038/s42003-023-05459-w.
Ref. 107. Terekhanova NV, et al. (2023) Nature, 623: 432. DOI: 10.1038/s41586-023-06682-5.
Ref. 108. Liu ZL, et al. (2023) Signal Transduct Target Ther, 8: 198. DOI: 10.1038/s41392-023-01460-1.
Ref. 109. Apte RS, et al. (2019) Cell, 176: 1248. DOI: 10.1016/j.cell.2019.01.021.
Ref. 110. Zhou H, et al. (2021) Cells, 10: 627. DOI: 10.3390/cells10030627.
Ref. 111. Padera TP, et al. (2016) Annu Rev Biomed Eng, 18: 125. DOI: 10.1146/annurev-bioeng-112315-031200.
Ref. 112. Hiam-Galvez KJ, et al. (2021) Nat Rev Cancer, 21: 345. DOI: 10.1038/s41568-021-00347-z.
Ref. 113. Spranger S, et al. (2018) Annu Rev Canc Biol, 2: 213. DOI: 10.1146/annurev-cancerbio-030617-050606.
Ref. 114. Kim SK, et al. (2022) Front Pharmacol, 13: 868695. DOI: 10.3389/fphar.2022.868695.
Ref. 115. Binnewies M, et al. (2018) Nat Med, 24: 541. DOI: 10.1038/s41591-018-0014-x.
Ref. 116. Ogunrinola GA, et al. (2020) Int J Microbiol, 2020: 8045646. DOI: 10.1155/2020/8045646.
Ref. 117. Pflughoeft KJ, et al. (2012) Annu Rev Pathol, 7: 99. DOI: 10.1146/annurev-pathol-011811-132421.
Ref. 118. de Vos WM, et al. (2022) Gut, 71: 1020. DOI: 10.1136/gutjnl-2021-326789.
Ref. 119. Kho ZY, et al. (2018) Front Microbiol, 9: 1835. DOI: 10.3389/fmicb.2018.01835.
Ref. 120. Schwabe RF, et al. (2013) Nat Rev Cancer, 13: 800. DOI: 10.1038/nrc3610.
Ref. 121. Cullin N, et al. (2021) Cancer Cell, 39: 1317. DOI: 10.1016/j.ccell.2021.08.006.
Ref. 122. Baker JL, et al. (2024) Nat Rev Microbiol, 22: 89. DOI: 10.1038/s41579-023-00963-6.
Ref. 123. Kyrgiou M, et al. (2022) Semin Cancer Biol, 86: 189. DOI: 10.1016/j.semcancer.2022.03.005.
Ref. 124. Sharifian K, et al. (2023) Virol J, 20: 73. DOI: 10.1186/s12985-023-02037-8.
Ref. 125. Chen Y, et al. (2022) Front Immunol, 13: 935846. DOI: 10.3389/fimmu.2022.935846.
Ref. 126. Battaglia TW, et al. (2024) Cell, 187: 2324. DOI: 10.1016/j.cell.2024.03.021.
Ref. 127. Villemin C, et al. (2023) Trends Immunol, 44: 44. DOI: 10.1016/j.it.2022.11.002.
Ref. 128. Byrd D, et al. (2024) Nat Rev Cancer, 24: 89. DOI: 10.1038/s41568-023-00638-7.
Ref. 129. Ahmad S, et al. (2022) World J Gastroenterol, 28: 2782. DOI: 10.3748/wjg.v28.i25.2782.
Ref. 130. Boire A, et al. (2024) Nat Rev Cancer, 00: s41568. DOI: 10.1038/s41568-024-00708-4.
Ref. 131. Zahir N, et al. (2020) Nat Genet, 52: 759. DOI: 10.1038/s41588-020-0668-4.
Ref. 132. de Visser KE, et al. (2023) Cancer Cell, 41: 374. DOI: 10.1016/j.ccell.2023.02.016.
Ref. 133. Bailey C, et al. (2021) Cancer Discov, 11: 916. Available from: https://doi.org/10.1158/2159-8290.CD-20-1559
Ref. 134. Dagogo-Jack I, et al. (2018) Nat Rev Clin Oncol, 15: 81. DOI: 10.1038/nrclinonc.2017.166.
Ref. 135. Mathur R, et al. (2024) Cell, 187: 446. DOI: 10.1016/j.cell.2023.12.013.
Ref. 136. Greenwald AC, et al. (2024) Cell, 187: 2485. DOI: 10.1016/j.cell.2024.03.029.
Ref. 137. Taylor MA, et al. (2024) Science, 384: eadi7453. DOI: 10.1126/science.adi7453.
Ref. 138. Braxton AM, et al. (2024) Nature, 629: 679. DOI: 10.1038/s41586-024-07359-3.
Ref. 139. George J, et al. (2024) Nature, 627: 880. DOI: 10.1038/s41586-024-07177-7.
Ref. 140. Nishimura T, et al. (2023) Nature, 620: 607. DOI: 10.1038/s41586-023-06333-9.
Ref. 141. Castaneda M, et al. (2022) Semin Cancer Biol, 87: 17. DOI: 10.1016/j.semcancer.2022.10.006.
Ref. 142. Marconi GD, et al. (2021) Cells, 10: 1587. DOI: 10.3390/cells10071587.
Ref. 143. Holly JM, et al. (2013) Cancer Metastasis Rev, 32: 673. DOI: 10.1007/s10555-013-9445-5.
Ref. 144. Pastushenko I, et al. (2019) Trends Cell Biol, 29: 212. DOI: 10.1016/j.tcb.2018.12.001.
Ref. 145. Brabletz T, et al. (2018) Nat Rev Cancer, 18: 128. DOI: 10.1038/nrc.2017.118.
Ref. 146. Fischer KR, et al. (2015) Nature, 527: 472. DOI: 10.1038/nature15748.
Ref. 147. Wang G, et al. (2021) NPJ Precis Oncol, 5: 56. DOI: 10.1038/s41698-021-00200-4.
Ref. 148. Lengrand J, et al. (2023) Nature, 620: 402. DOI: 10.1038/s41586-023-06372-2.
Ref. 149. Cassier PA, et al. (2023) Nature, 620: 409. DOI: 10.1038/s41586-023-06367-z.
Ref. 150. Jin MZ, et al. (2020) Signal Transduct Target Ther, 5: 166. DOI: 10.1038/s41392-020-00280-x.
References 151-200
Ref. 151. Anderson NM, et al. (2020) Curr Biol, 30: R921. DOI: 10.1016/j.cub.2020.06.081.
Ref. 152. Bejarano L, et al. (2021) Cancer Discov, 11: 933. Available from: https://doi.org/10.1158/2159-8290.CD-20-1808
Ref. 153. No Authors (2024) Nat Biotechnol, 42: 349. DOI: 10.1038/s41587-024-02195-2.
Ref. 154. Zhang J, et al. (2015) N Engl J Med, 373: 2336. DOI: 10.1056/NEJMoa1508054.
Ref. 155. Parsons DW, et al. (2016) JAMA Oncol, 2: 616. DOI: 10.1001/jamaoncol.2015.5699.
Ref. 156. Fiala EM, et al. (2021) Nat Cancer, 2: 357. DOI: 10.1038/s43018-021-00172-1.
Ref. 157. Grobner SN, et al. (2018) Nature, 555: 321. DOI: 10.1038/nature25480.
Ref. 158. Gore L, et al. (2024) Cell, 187: 1584. DOI: 10.1016/j.cell.2024.02.039.
Ref. 159. Sweet-Cordero EA, et al. (2019) Science, 363: 1170. DOI: 10.1126/science.aaw3535.
Ref. 160. Liu Y, et al. (2023) Nat Commun, 14: 1739. DOI: 10.1038/s41467-023-37438-4.
Ref. 161. Vellichirammal NN, et al. (2021) Cancer Lett, 499: 24. DOI: 10.1016/j.canlet.2020.11.015.
Ref. 162. Seong BKA, et al. (2021) Cancer Cell, 39: 1262. DOI: 10.1016/j.ccell.2021.07.003.
Ref. 163. Rossi A, et al. (2008) Clin Cancer Res, 14: 971. Available from: https://doi.org/10.1158/1078-0432.CCR-07-2072
Ref. 164. Gajjar A, et al. (2021) J Clin Oncol, 39: 822. DOI: 10.1200/JCO.20.01372.
Ref. 165. Roberts KG, et al. (2014) N Engl J Med, 371: 1005. DOI: 10.1056/NEJMoa1403088.
Ref. 166. Malone ER, et al. (2020) Genome Med, 12: 8. DOI: 10.1186/s13073-019-0703-1.
Ref. 167. Adashek JJ, et al. (2021) Trends Cancer, 7: 15. DOI: 10.1016/j.trecan.2020.08.009.
Ref. 168. Besse B, et al. (2024) Nat Med, 30: 716. DOI: 10.1038/s41591-024-02808-y.
Ref. 169. Mani DR, et al. (2022) Nat Rev Cancer, 22: 298. DOI: 10.1038/s41568-022-00446-5.
Ref. 170. Wahida A, et al. (2023) Nat Rev Cancer, 23: 43. DOI: 10.1038/s41568-022-00529-3.
Ref. 171. Mateo J, et al. (2022) Nat Med, 28: 658. DOI: 10.1038/s41591-022-01717-2.
Ref. 172. Richman IB, et al. (2023) JAMA Netw Open, 6: e234898. DOI: 10.1001/jamanetworkopen.2023.4898.
Ref. 173. Bradley AC, et al. (2024) Environ Sci Technol, 58: 4226. DOI: 10.1021/acs.est.3c03230.
Ref. 174. Tessum CW, et al. (2021) Sci Adv, 7: eabf4491. DOI: 10.1126/sciadv.abf4491.
Ref. 175. Carroll R, et al. (2023) Environ Res, 239: 117349. DOI: 10.1016/j.envres.2023.117349.
Ref. 176. Cheng I, et al. (2022) Am J Respir Crit Care Med, 206: 1008. DOI: 10.1164/rccm.202107-1770OC.
Ref. 177. Yazzie SA, et al. (2020) Int J Environ Res Public Health, 17: 2813. DOI: 10.3390/ijerph17082813.
Ref. 178. Warren GW, et al. (2013) Am Soc Clin Oncol Educ Book, 33: 359. DOI: 10.14694/EdBook_AM.2013.33.359.
Ref. 179. Jha P, et al. (2013) N Engl J Med, 368: 341. DOI: 10.1056/NEJMsa1211128.
Ref. 180. Alexandrov LB, et al. (2016) Science, 354: 618. DOI: 10.1126/science.aag0299.
Ref. 181. Pezzuto A, et al. (2019) Future Sci OA, 5: FSO394. DOI: 10.2144/fsoa-2019-0017.
Ref. 182. Yang Y, et al. (2023) J Hazard Mater, 455: 131556. DOI: 10.1016/j.jhazmat.2023.131556.
Ref. 183. Shreves AH, et al. (2023) Cancer Epidemiol Biomarkers Prev, 32: 193. Available from: https://doi.org/10.1158/1055-9965.EPI-22-0253
Ref. 184. Loretan CG, et al. (2022) Prev Chronic Dis, 19: E87. DOI: 10.5888/pcd19.220184.
Ref. 185. Birdsey J, et al. (2023) MMWR Morb Mortal Wkly Rep, 72: 1173. DOI: 10.15585/mmwr.mm7244a1.
Ref. 186. Villanti AC, et al. (2021) Nicotine Tob Res, 23: 1318. DOI: 10.1093/ntr/ntaa224.
Ref. 187. Watkins SL, et al. (2022) J Adolesc Health, 71: 226. DOI: 10.1016/j.jadohealth.2022.02.013.
Ref. 188. Villanti AC, et al. (2016) Tob Control, 25: ii14. DOI: 10.1136/tobaccocontrol-2016-053329.
Ref. 189. Ahmed AA, et al. (2015) Circ Heart Fail, 8: 694. DOI: 10.1161/CIRCHEARTFAILURE.114.001885.
Ref. 190. Duncan MS, et al. (2019) JAMA, 322: 642. DOI: 10.1001/jama.2019.10298.
Ref. 191. Thomson B, et al. (2022) JAMA Netw Open, 5: e2231480. DOI: 10.1001/jamanetworkopen.2022.31480.
Ref. 192. Fu SS, et al. (2023) JAMA Netw Open, 6: e2329903. DOI: 10.1001/jamanetworkopen.2023.29903.
Ref. 193. Flor LS, et al. (2024) Nat Med, 30: 149. DOI: 10.1038/s41591-023-02743-4.
Ref. 194. Brody D, et al. (2021) MMWR Morb Mortal Wkly Rep, 70: 224. DOI: 10.15585/mmwr.mm7006a6.
Ref. 195. US Department of Health and Human Services. The Health Consequences of Smoking—50 Years of Progress A Report of the Surgeon General. Accessed: March 17, 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK179276/
Ref. 196. Centers for Disease Control and Prevention. Youth and Tobacco Use | Smoking and Tobacco Use. Accessed: Available from: https://www.cdc.gov/tobacco/data_statistics/fact_sheets/youth_data/tobacco_use/index.htm
Ref. 197. Le TTT (2023) JAMA Netw Open, 6: e2337101. DOI: 10.1001/jamanetworkopen.2023.37101.
Ref. 198. Auer R, et al. (2024) N Engl J Med, 390: 601. DOI: 10.1056/NEJMoa2308815.
Ref. 199. Prochaska JJ, et al. (2022) Tob Control, 31: e88. DOI: 10.1136/tobaccocontrol-2020-056367.
Ref. 200. Erhabor J, et al. (2023) JAMA Netw Open, 6: e2340859. DOI: 10.1001/jamanetworkopen.2023.40859.
References 201-250
Ref. 201. Goniewicz ML, et al. (2018) JAMA Netw Open, 1: e185937. DOI: 10.1001/jamanetworkopen.2018.5937.
Ref. 202. Herbst RS, et al. (2022) Clin Cancer Res, 28: 4861. Available from: https://doi.org/10.1158/1078-0432.CCR-22-2429
Ref. 203. Ghasemiesfe M, et al. (2019) JAMA Netw Open, 2: e1916318. DOI: 10.1001/jamanetworkopen.2019.16318.
Ref. 204. Pew Research Center. Most Americans Now Live in a Legal Marijuana State – and Most Have At Least One Dispensary in Their County. Accessed: March 26, 2024. Available from: https://www.pewresearch.org/short-reads/2024/02/29/most-americans-now-live-in-a-legal-marijuana-state-and-most-have-at-least-one-dispensary-in-their-county/
Ref. 205. Dai HD, et al. (2023) JAMA Netw Open, 6: e2329167. DOI: 10.1001/jamanetworkopen.2023.29167.
Ref. 206. Islami F, et al. (2018) CA Cancer J Clin, 68: 31. DOI: 10.3322/caac.21440.
Ref. 207. Islami F, et al. (2019) JAMA Oncol, 5: 384. DOI: 10.1001/jamaoncol.2018.5639.
Ref. 208. Piercy KL, et al. (2018) JAMA, 320: 2020. DOI: 10.1001/jama.2018.14854.
Ref. 209. Matthews CE, et al. (2020) J Clin Oncol, 38: 686. DOI: 10.1200/Jco.19.02407.
Ref. 210. Patel AV, et al. (2019) Med Sci Sports Exerc, 51: 2391. DOI: 10.1249/MSS.0000000000002117.
Ref. 211. Moore SC, et al. (2016) JAMA Intern Med, 176: 816. DOI: 10.1001/jamainternmed.2016.1548.
Ref. 212. World Cancer Research Fund/American Institute for Cancer Research. Continuous Update Project. Expert Report 2018. Lactation and the Risk of Cancer. Accessed: July 6, 2023. Available from: https://www.wcrf.org/diet-activity-and-cancer/
Ref. 213. Clinton SK, et al. (2020) J Nutr, 150: 663. DOI: 10.1093/jn/nxz268.
Ref. 214. Lauby-Secretan B, et al. (2016) N Engl J Med, 375: 794. DOI: 10.1056/NEJMsr1606602.
Ref. 215. Centers for Disease Control and Prevention. Adult Obesity Facts. Accessed: March 17, 2024. Available from: https://www.cdc.gov/obesity/data/adult.html
Ref. 216. World Health Organization. Obesity and Overweight. Accessed: July 10, 2024. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
Ref. 217. Centers for Disease Control and Prevention. BRFSS Prevalence Data & Data Analysis Tools. Accessed: July 10, 2024. Available from: https://www.cdc.gov/brfss/data_tools.htm
Ref. 218. Tan DJH, et al. (2024) Metabolism, 152: 155744. DOI: 10.1016/j.metabol.2023.155744.
Ref. 219. Schauer DP, et al. (2017) Obesity (Silver Spring), 25 Suppl 2: S52. DOI: 10.1002/oby.22002.
Ref. 220. Bruno DS, et al. (2020) Ann Transl Med, 8: S13. DOI: 10.21037/atm.2019.09.26.
Ref. 221. Adams TD, et al. (2023) Obesity (Silver Spring), 31: 574. DOI: 10.1002/oby.23646.
Ref. 222. Aminian A, et al. (2022) JAMA, 327: 2423. DOI: 10.1001/jama.2022.9009.
Ref. 223. Wang L, et al. (2024) JAMA Oncol, 10: 256. DOI: 10.1001/jamaoncol.2023.5573.
Ref. 224. Morales-Berstein F, et al. (2024) Eur J Nutr, 63: 377. DOI: 10.1007/s00394-023-03270-1.
Ref. 225. Jin Q, et al. (2023) Br J Cancer, 129: 1978. DOI: 10.1038/s41416-023-02469-7.
Ref. 226. Chang K, et al. (2023) EClinicalMedicine, 56: 101840. DOI: 10.1016/j.eclinm.2023.101840.
Ref. 227. Centers for Disease Control and Prevention. Fast Food Consumption Among Adults in the United States, 2013–2016. Accessed: July 5, 2023. Available from: https://www.cdc.gov/nchs/products/databriefs/db322.htm
Ref. 228. Meine GC, et al. (2024) Am J Gastroenterol, 119: 1056. DOI: 10.14309/ajg.0000000000002826.
Ref. 229. Caceres-Matos R, et al. (2024) Gastrointest Disord, 6: 164. DOI: 10.3390/gidisord6010012
Ref. 230. Visioli F, et al. (2024) Lancet Reg Health Eur, 38: 100863. DOI: 10.1016/j.lanepe.2024.100863.
Ref. 231. Sivasubramanian BP, et al. (2023) Cureus, 15: e45324. DOI: 10.7759/cureus.45324.
Ref. 232. Di Y, et al. (2023) BMC Cancer, 23: 782. DOI: 10.1186/s12885-023-11218-1.
Ref. 233. Kim Y (2023) Cancer Causes Control, 34: 569. DOI: 10.1007/s10552-023-01698-8.
Ref. 234. Zhao L, et al. (2023) JAMA, 330: 537. DOI: 10.1001/jama.2023.12618.
Ref. 235. Feng L, et al. (2023) Eur J Clin Nutr, 77: 941. DOI: 10.1038/s41430-023-01302-x.
Ref. 236. de Lorgeril M, et al. (2020) Transl Cancer Res, 9: 3172. DOI: 10.21037/tcr-2020-003.
Ref. 237. McCullough ML, et al. (2022) Cancer Epidemiol Biomarkers Prev, 31: 1907. Available from: https://doi.org/10.1158/1055-9965.EPI-22-0392
Ref. 238. Tseng TS, et al. (2021) World J Diabetes, 12: 1530. DOI: 10.4239/wjd.v12.i9.1530.
Ref. 239. Heo GY, et al. (2024) JAMA Netw Open, 7: e2356885. DOI: 10.1001/jamanetworkopen.2023.56885.
Ref. 240. Cai XY, et al. (2022) Clin Kidney J, 15: 718. DOI: 10.1093/ckj/sfab227.
Ref. 241. Goncalves MD, et al. (2019) Science, 363: 1345. DOI: 10.1126/science.aat8515.
Ref. 242. Hua SV, et al. (2023) JAMA Netw Open, 6: e2323200. DOI: 10.1001/jamanetworkopen.2023.23200.
Ref. 243. Kaplan S, et al. (2024) JAMA Health Forum, 5: e234737. DOI: 10.1001/jamahealthforum.2023.4737.
Ref. 244. Bleich SN, et al. (2021) JAMA Netw Open, 4: e2113527. DOI: 10.1001/jamanetworkopen.2021.13527.
Ref. 245. Bui LP, et al. (2024) Am J Clin Nutr, 120: 80. DOI: 10.1016/j.ajcnut.2024.03.019.
Ref. 246. Cai Y, et al. (2024) Am J Clin Nutr, 119: 406. DOI: 10.1016/j.ajcnut.2023.11.015.
Ref. 247. Hang D, et al. (2023) J Natl Cancer Inst, 115: 155. DOI: 10.1093/jnci/djac221.
Ref. 248. Lopez-Bueno R, et al. (2023) JAMA Intern Med, 183: 982. DOI: 10.1001/jamainternmed.2023.3093.
Ref. 249. Minihan AK, et al. (2022) Med Sci Sports Exerc, 54: 417. DOI: 10.1249/MSS.0000000000002801.
Ref. 250. Katsaroli I, et al. (2024) Med Sci Sports Exerc, 56: 1134. DOI: 10.1249/MSS.0000000000003385.
References 251-300
Ref. 251. Withall J, et al. (2011) BMC Public Health, 11: 507. DOI: 10.1186/1471-2458-11-507.
Ref. 252. Patel NA, et al. (2022) Kans J Med, 15: 267. DOI: 10.17161/kjm.vol15.17592.
Ref. 253. Engelberg JK, et al. (2016) BMC Public Health, 16: 395. DOI: 10.1186/s12889-016-3055-4.
Ref. 254. Thornton CM, et al. (2016) SSM Popul Health, 2: 206. DOI: 10.1016/j.ssmph.2016.03.004.
Ref. 255. Centers for Disease Control and Prevention. Physical Inactivity is More Common among Racial and Ethnic Minorities in Most States. Accessed: July 5, 2023. Available from: https://blogs.cdc.gov/healthequity/2020/04/01/physical-inactivity/
Ref. 256. Abildso CG, et al. (2023) MMWR Morb Mortal Wkly Rep, 72: 85. DOI: 10.15585/mmwr.mm7204a1.
Ref. 257. Gentiluomo M, et al. (2024) J Endocr Soc, 8: bvae017. DOI: 10.1210/jendso/bvae017.
Ref. 258. The Ohio State University Comprehensive Cancer Center. Survey: Many People Don’t Know Alcohol, High Fat Processed Foods, and Lack of Exercise Are Risk Factors for Colorectal Cancer. Accessed: July 10, 2024. Available from: https://cancer.osu.edu/news/many-people-do-not-know-risk-factors-for-colorectal-cancer
Ref. 259. Yoo JE, et al. (2022) JAMA Netw Open, 5: e2228544. DOI: 10.1001/jamanetworkopen.2022.28544.
Ref. 260. Lee AK, et al. (2023) JAMA Intern Med, 183: 319. DOI: 10.1001/jamainternmed.2022.7083.
Ref. 261. McPheeters M, et al. (2023) JAMA, 330: 1653. DOI: 10.1001/jama.2023.19761.
Ref. 262. Phillips JA (2021) Workplace Health Saf, 69: 395. DOI: 10.1177/21650799211026980.
Ref. 263. Strome A, et al. (2021) JAMA Netw Open, 4: e2134550. DOI: 10.1001/jamanetworkopen.2021.34550.
Ref. 264. Centers for Disease Control and Prevention. Youth Risk Behavior Surveillance System (YRBSS). Accessed: July 5, 2023. Available from: https://www.cdc.gov/healthyyouth/data/yrbs/index.htm
Ref. 265. Centers for Disease Control and Prevention. National Health Interview Survey. Accessed: July 5, 2023. Available from: https://www.cdc.gov/nchs/nhis/index.htm
Ref. 266. Wu S, et al. (2016) Am J Epidemiol, 183: 824. DOI: 10.1093/aje/kwv282.
Ref. 267. Wu S, et al. (2014) Cancer Epidemiol Biomarkers Prev, 23: 1080. Available from: https://doi.org/10.1158/1055-9965.EPI-13-0821
Ref. 268. Holman DM, et al. (2019) J Community Health, 44: 1086. DOI: 10.1007/s10900-019-00685-y.
Ref. 269. Skin Cancer Foundation. Indoor Tanning Legislation: Here’s Where We Stand. Accessed: July 5, 2023. Available from: https://www.skincancer.org/blog/indoor-tanning-legislation-heres-stand/
Ref. 270. National Cancer Institute. HPV and Cancer. Accessed: August 11, 2022. Available from: https://www.cancer.gov/about-cancer/causes-prevention/risk/infectious-agents/hpv-and-cancer
Ref. 271. Centers for Disease Control and Prevention. 2022 Hepatitis C. Viral Hepatitis Surveillance Report. Accessed: July 7, 2024. Available from: https://www.cdc.gov/hepatitis/statistics/2022surveillance/hepatitis-c.htm
Ref. 272. Centers for Disease Control and Prevention. 2020 Hepatitis B. Viral Hepatitis Surveillance Report. Accessed: March 26, 2024. Available from: https://www.cdc.gov/hepatitis/statistics/2020surveillance/hepatitis-b.htm
Ref. 273. Han Z, et al. (2023) Helicobacter, 28: e12950. DOI: 10.1111/hel.12950.
Ref. 274. Kumar S, et al. (2020) Gastroenterology, 158: 527. DOI: 10.1053/j.gastro.2019.10.019.
Ref. 275. Parsonnet J, et al. (1994) N Engl J Med, 330: 1267. DOI: 10.1056/NEJM199405053301803.
Ref. 276. Stathis A, et al. (2009) Ann Oncol, 20: 1086. DOI: 10.1093/annonc/mdn760.
Ref. 277. Kiesewetter B, et al. (2013) Blood, 122: 1350. DOI: 10.1182/blood-2013-02-486522.
Ref. 278. Lai Y, et al. (2022) Front Public Health, 10: 1056157. DOI: 10.3389/fpubh.2022.1056157.
Ref. 279. American Cancer Society. Stomach (Gastric) Cancer Key Statistics. Accessed: August 7, 2024. Available from: https://www.cancer.org/cancer/types/stomach-cancer/about/key-statistics.html
Ref. 280. Garman KS, et al. (2024) Gastric Cancer, 27: 28. DOI: 10.1007/s10120-023-01448-4.
Ref. 281. US Global Change Research Program. Fourth National Climate Assessment. Volume II: Impacts, Risks, and Adaptation in the United States. Accessed: March 17, 2024. Available from: https://nca2018.globalchange.gov/downloads/NCA2018_FullReport.pdf
Ref. 282. Lopez AM, et al. (2023) Nat Commun, 14: 8007. DOI: 10.1038/s41467-023-43101-9.
Ref. 283. Riudavets M, et al. (2022) Cancers (Basel), 14: 3142. DOI: 10.3390/cancers14133142.
Ref. 284. Liu Y, et al. (2024) Crit Rev Oncol Hematol, 198: 104363. DOI: 10.1016/j.critrevonc.2024.104363.
Ref. 285. United States Environmental Protection Agency. Health Risk of Radon. Accessed: July 7, 2024. Available from: https://www.epa.gov/radon/health-risk-radon
Ref. 286. Jephcote C, et al. (2020) Environ Health, 19: 53. DOI: 10.1186/s12940-020-00582-1.
Ref. 287. van Gerwen M, et al. (2023) EBioMedicine, 97: 104831. DOI: 10.1016/j.ebiom.2023.104831.
Ref. 288. Liu H, et al. (2023) Front Oncol, 13: 1282651. DOI: 10.3389/fonc.2023.1282651.
Ref. 289. Loomis D, et al. (2013) Lancet Oncol, 14: 1262. DOI: 10.1016/s1470-2045(13)70487-x.
Ref. 290. Berg CD, et al (2023) J Thorac Oncol, 18: 1277. DOI: 10.1016/j.jtho.2023.05.024.
Ref. 291. Shen J, et al. (2017) Br J Cancer, 116: 1229. DOI: 10.1038/bjc.2017.81.
Ref. 292. Korsh J, et al. (2015) Breast Care (Basel), 10: 316. DOI: 10.1159/000436956.
Ref. 293. Liu B, et al. (2024) JAMA Netw Open, 7: e243127. DOI: 10.1001/jamanetworkopen.2024.3127.
Ref. 294. Hoehn RM, et al. (2024) Environ Sci Technol, 58: 8825. DOI: 10.1021/acs.est.3c10440.
Ref. 295. Chang CJ, et al. (2022) J Natl Cancer Inst, 114: 1636. DOI: 10.1093/jnci/djac165.
Ref. 296. Bertrand KA, et al. (2023) Environ Res, 239: 117228. DOI: 10.1016/j.envres.2023.117228.
Ref. 297. Llanos AAM, et al. (2017) Carcinogenesis, 38: 883. DOI: 10.1093/carcin/bgx060.
Ref. 298. Morris RD (1995) Environ Health Perspect, 103 Suppl 8: 225. DOI: 10.1289/ehp.95103s8225.
Ref. 299. Harris RB, et al. (2022) Int J Environ Res Public Health, 19: 797. DOI: 10.3390/ijerph19020797.
Ref. 300. Tanana H, et al. (2021) Health Secur, 19: S78. DOI: 10.1089/hs.2021.0034.
References 301-350
Ref. 301. Wroblewski LE, et al. (2010) Clin Microbiol Rev, 23: 713. DOI: 10.1128/CMR.00011-10.
Ref. 302. Liddie JM, et al. (2023) Environmental Science & Technology, 57: 7902. DOI: 10.1021/acs.est.2c07255.
Ref. 303. Lee DJ, et al. (2023) Front Oncol, 13: 1130754. DOI: 10.3389/fonc.2023.1130754.
Ref. 304. Kunz KR, et al. (2023) Front Public Health, 11: 1126066. DOI: 10.3389/fpubh.2023.1126066.
Ref. 305. McDermott JE, et al. (2024) J Proteome Res, 23: 1547. DOI: 10.1021/acs.jproteome.3c00418.
Ref. 306. International Agency for Research on Cancer Working Group on the Identification of Carcinogenic Hazards to Humans. Night Shift Work. Accessed: March 17, 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK568199/
Ref. 307. Huang C, et al. (2023) Cancer Biol Med, 20: 1. DOI: 10.20892/j.issn.2095-3941.2022.0474.
Ref. 308. Sahin L, et al. (2022) Lighting Research & Technology, 54: 441. DOI: 10.1177/14771535211040985.
Ref. 309. Figueiro MG, et al. (2010) Int J Endocrinol, 2010: 829351. DOI: 10.1155/2010/829351.
Ref. 310. Faraut B, et al. (2019) Front Neurosci, 13: 1366. DOI: 10.3389/fnins.2019.01366.
Ref. 311. Nichols HB, et al. (2019) Ann Intern Med, 170: 22. DOI: 10.7326/M18-1323.
Ref. 312. Ambrosone CB, et al. (2020) Cancer Res, 80: 4871. Available from: https://doi.org/10.1158/0008-5472.CAN-20-0077
Ref. 313. Jung AY, et al. (2022) J Natl Cancer Inst, 114: 1706. DOI: 10.1093/jnci/djac117.
Ref. 314. Proussaloglou EM, et al. (2023) Pathol Res Pract, 244: 154413. DOI: 10.1016/j.prp.2023.154413.
Ref. 315. Vohra SN, et al. (2022) Cancer Epidemiol Biomarkers Prev, 31: 561. Available from: https://doi.org/10.1158/1055-9965.EPI-21-0940
Ref. 316. John EM, et al. (2024) Breast Cancer Res, 26: 88. DOI: 10.1186/s13058-024-01834-5.
Ref. 317. Millikan RC, et al. (2008) Breast Cancer Res Treat, 109: 123. DOI: 10.1007/s10549-007-9632-6.
Ref. 318. Lord SJ, et al. (2008) Cancer Epidemiol Biomarkers Prev, 17: 1723. Available from: https://doi.org/10.1158/1055-9965.EPI-07-2824
Ref. 319. Fortner RT, et al. (2019) Breast Cancer Res, 21: 40. DOI: 10.1186/s13058-019-1119-y.
Ref. 320. Anstey EH, et al. (2017) Am J Prev Med, 53: S40. DOI: 10.1016/j.amepre.2017.04.024.
Ref. 321. Palmer JR, et al. (2014) J Natl Cancer Inst, 106: dju237. DOI: 10.1093/jnci/dju237.
Ref. 322. John EM, et al. (2018) Int J Cancer, 142: 2273. DOI: 10.1002/ijc.31258.
Ref. 323. Mao X, et al. (2023) BMC Cancer, 23: 644. DOI: 10.1186/s12885-023-11049-0.
Ref. 324. Chlebowski RT, et al. (2020) JAMA, 324: 369. DOI: 10.1001/jama.2020.9482.
Ref. 325. Chlebowski RT, et al. (2008) Arch Intern Med, 168: 370. DOI: 10.1001/archinternmed.2007.123.
Ref. 326. Chlebowski RT, et al. (2009) N Engl J Med, 360: 573. DOI: 10.1056/NEJMoa0807684.
Ref. 327. Collaborative Group on Hormonal Factors in Breast C (2019) Lancet, 394: 1159. DOI: 10.1016/S0140-6736(19)31709-X.
Ref. 328. Wang SM, et al. (2020) Breast Cancer Res, 22: 129. DOI: 10.1186/s13058-020-01365-9.
Ref. 329. Jackson SS, et al. (2022) Trends Cancer, 8: 273. DOI: 10.1016/j.trecan.2022.01.005.
Ref. 330. de Blok CJM, et al. (2019) BMJ, 365: l1652. DOI: 10.1136/bmj.l1652.
Ref. 331. de Nie I, et al. (2020) J Clin Endocrinol Metab, 105: e3293. DOI: 10.1210/clinem/dgaa412.
Ref. 332. Raths F, et al. (2023) Cell Genom, 3: 100272. DOI: 10.1016/j.xgen.2023.100272.
Ref. 333. Hofseth LJ, et al. (2020) Nat Rev Gastroenterol Hepatol, 17: 352. DOI: 10.1038/s41575-019-0253-4.
Ref. 334. Nguyen LH, et al. (2018) JNCI Cancer Spectr, 2: pky073. DOI: 10.1093/jncics/pky073.
Ref. 335. Liu PH, et al. (2019) JAMA Oncol, 5: 37. DOI: 10.1001/jamaoncol.2018.4280.
Ref. 336. Hur J, et al. (2021) Eur J Epidemiol, 36: 325. DOI: 10.1007/s10654-021-00723-x.
Ref. 337. Laiyemo AO, et al. (2022) Gastroenterology, 162: 1026. DOI: 10.1053/j.gastro.2022.01.041.
Ref. 338. Rudant J, et al. (2008) Cancer Causes Control, 19: 1277. DOI: 10.1007/s10552-008-9199-5.
Ref. 339. Metayer C, et al. (2013) Cancer Epidemiol Biomarkers Prev, 22: 1600. Available from: https://doi.org/10.1158/1055-9965.EPI-13-0350
Ref. 340. Chang JS, et al. (2006) Am J Epidemiol, 163: 1091. DOI: 10.1093/aje/kwj143.
Ref. 341. Boffetta P, et al. (2000) Environ Health Perspect, 108: 73. DOI: 10.1289/ehp.0010873.
Ref. 342. Centers for Disease Control and Prevention. Smoking, Pregnancy, and Babies. Accessed: July 7, 2024. Available from: https://www.cdc.gov/tobacco/campaign/tips/diseases/pregnancy.html
Ref. 343. Stjernfeldt M, et al. (1986) Lancet, 1: 1350. DOI: 10.1016/s0140-6736(86)91664-8.
Ref. 344. Rumrich IK, et al. (2016) PLoS One, 11: e0165040. DOI: 10.1371/journal.pone.0165040.
Ref. 345. Heck JE, et al. (2016) Int J Cancer, 139: 613. DOI: 10.1002/ijc.30111.
Ref. 346. Metayer C, et al. (2024) Cancer Epidemiol Biomarkers Prev, 33: 117. Available from: https://doi.org/10.1158/1055-9965.EPI-23-0801
Ref. 347. Milne E, et al. (2012) Am J Epidemiol, 175: 43. DOI: 10.1093/aje/kwr275.
Ref. 348. Chunxia D, et al. (2019) Medicine (Baltimore), 98: e16454. DOI: 10.1097/MD.0000000000016454.
Ref. 349. Edraki M, et al. (2011) East Mediterr Health J, 17: 303.
Ref. 350. Tredaniel J, et al. (1994) Paediatr Perinat Epidemiol, 8: 233. DOI: 10.1111/j.1365-3016.1994.tb00455.x.
References 351-400
Ref. 351. Jacob A, et al. (2020) J Clin Oncol, 38: e13626. DOI: 10.1200/JCO.2020.38.15_suppl.e13626.
Ref. 352. Jensen BW, et al. (2023) J Natl Cancer Inst, 115: 43. DOI: 10.1093/jnci/djac192.
Ref. 353. Onerup A, et al. (2024) Obesity (Silver Spring), 32: 376. DOI: 10.1002/oby.23942.
Ref. 354. Han Y, et al. (2024) Breast Cancer Res, 26: 39. DOI: 10.1186/s13058-024-01804-x.
Ref. 355. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey 2017–March 2020 Prepandemic Data Files Development of Files and Prevalence Estimates for Selected Health Outcomes. Accessed: March 17, 2024. Available from: https://stacks.cdc.gov/view/cdc/106273
Ref. 356. Rahib L, et al. (2021) JAMA Netw Open, 4: e214708. DOI: 10.1001/jamanetworkopen.2021.4708.
Ref. 357. Saraiva MR, et al. (2023) World J Gastroenterol, 29: 1289. DOI: 10.3748/wjg.v29.i8.1289.
Ref. 358. Laskar RS, et al. (2024) Ann Oncol, 35: 523. DOI: 10.1016/j.annonc.2024.02.008.
Ref. 359. Chen J, et al. (2024) Int J Cancer, 154: 1930. DOI: 10.1002/ijc.34887.
Ref. 360. Dai R, et al. (2024) Cancers (Basel), 16: 676. DOI: 10.3390/cancers16030676.
Ref. 361. Hu K, et al. (2023) J Nutr Educ Behav, 55: 851. DOI: 10.1016/j.jneb.2023.10.003.
Ref. 362. Lipsky LM, et al. (2017) Am J Clin Nutr, 105: 1424. DOI: 10.3945/ajcn.116.150029.
Ref. 363. Livingstone KM, et al. (2023) Int J Behav Nutr Phys Act, 20: 70. DOI: 10.1186/s12966-023-01477-3.
Ref. 364. Joh HK, et al. (2021) Gastroenterology, 161: 128. DOI: 10.1053/j.gastro.2021.03.028.
Ref. 365. Hur J, et al. (2021) Gut, 70: 2330. DOI: 10.1136/gutjnl-2020-323450.
Ref. 366. Jiang F, et al. (2023) Int J Cancer, 153: 1602. DOI: 10.1002/ijc.34648.
Ref. 367. McDowell R, et al. (2022) Br J Cancer, 126: 957. DOI: 10.1038/s41416-021-01665-7.
Ref. 368. Chao C, et al. (2024) J Clin Oncol, 42: e15653. DOI: 10.1200/JCO.2024.42.16_suppl.e15653.
Ref. 369. Kuzik N, et al. (2023) Front Public Health, 11: 1172168. DOI: 10.3389/fpubh.2023.1172168.
Ref. 370. Telama R, et al. (2005) Am J Prev Med, 28: 267. DOI: 10.1016/j.amepre.2004.12.003.
Ref. 371. Fraser BJ, et al. (2017) J Sci Med Sport, 20: 927. DOI: 10.1016/j.jsams.2017.03.021.
Ref. 372. Pongiglione B, et al. (2020) Int J Epidemiol, 49: 1749. DOI: 10.1093/ije/dyaa131.
Ref. 373. Onerup A, et al. (2023) Br J Sports Med, 57: 1248. DOI: 10.1136/bjsports-2022-106617.
Ref. 374. Jensen MT, et al. (2017) Br J Sports Med, 51: 1364. DOI: 10.1136/bjsports-2016-096860.
Ref. 375. Centers for Disease Control and Prevention. Physical Activity Among Adults Aged 18 and Over: United States, 2020. Accessed: July 7, 2024. Available from: https://stacks.cdc.gov/view/cdc/120213
Ref. 376. Orsi L, et al. (2015) Cancer Causes Control, 26: 1003. DOI: 10.1007/s10552-015-0593-5.
Ref. 377. Karalexi MA, et al. (2017) Eur J Cancer Prev, 26: 433. DOI: 10.1097/CEJ.0000000000000350.
Ref. 378. Mayen AL, et al. (2022) Eur J Epidemiol, 37: 915. DOI: 10.1007/s10654-022-00900-6.
Ref. 379. Jin EH, et al. (2023) J Clin Oncol, 41: 3816. DOI: 10.1200/JCO.22.01895.
Ref. 380. O’Sullivan DE, et al. (2022) Clin Gastroenterol Hepatol, 20: 1229. DOI: 10.1016/j.cgh.2021.01.037.
Ref. 381. Chen X, et al. (2022) EClinicalMedicine, 49: 101460. DOI: 10.1016/j.eclinm.2022.101460.
Ref. 382. Mix JM, et al. (2021) Cancer Epidemiol Biomarkers Prev, 30: 30. Available from: https://doi.org/10.1158/1055-9965.EPI-20-0846
Ref. 383. Swiecki-Sikora AL, et al. (2019) J Rural Health, 35: 506. DOI: 10.1111/jrh.12353.
Ref. 384. Pingali C, et al. (2023) MMWR Morb Mortal Wkly Rep, 72: 912. DOI: 10.15585/mmwr.mm7234a3.
Ref. 385. Australian Government Department of Health and Aged Care. Human papillomavirus (HPV) immunisation data. Accessed: August 7, 2024. Available from: https://www.health.gov.au/topics/immunisation/immunisation-data/human-papillomavirus-hpv-immunisation-data
Ref. 386. UK Health Security Agency. Human papillomavirus (HPV) vaccination coverage in adolescents in England: 2022 to 2023. Accessed: August 7, 2024. Available from: https://www.gov.uk/government/statistics/human-papillomavirus-hpv-vaccine-coverage-estimates-in-england-2022-to-2023/human-papillomavirus-hpv-vaccination-coverage-in-adolescents-in-england-2022-to-2023
Ref. 387. Centers for Disease Control and Prevention. Human Papillomavirus Vaccination Coverage in Children Ages 9–17 Years: United States, 2022. Accessed: August 7, 2024. Available from: https://www.cdc.gov/nchs/products/databriefs/db495.htm
Ref. 388. Palmer TJ, et al. (2024) J Natl Cancer Inst, 116: 857. DOI: 10.1093/jnci/djad263.
Ref. 389. Karalexi MA, et al. (2021) Environ Pollut, 285: 117376. DOI: 10.1016/j.envpol.2021.117376.
Ref. 390. Gunier RB, et al. (2017) Environ Res, 156: 57. DOI: 10.1016/j.envres.2017.03.001.
Ref. 391. Patel DM, et al. (2020) Int J Cancer, 146: 943. DOI: 10.1002/ijc.32388.
Ref. 392. Hyland C, et al. (2018) Int J Cancer, 143: 1295. DOI: 10.1002/ijc.31522.
Ref. 393. Park AS, et al. (2020) Int J Hyg Environ Health, 226: 113486. DOI: 10.1016/j.ijheh.2020.113486.
Ref. 394. Rossides M, et al. (2022) Environ Health Perspect, 130: 77002. DOI: 10.1289/EHP11035.
Ref. 395. Savitz DA, et al. (1990) Environ Health Perspect, 88: 325. DOI: 10.1289/ehp.9088325.
Ref. 396. Onyije FM, et al. (2022) Environ Int, 167: 107409. DOI: 10.1016/j.envint.2022.107409.
Ref. 397. Ou JY, et al. (2020) Cancer Epidemiol Biomarkers Prev, 29: 1929. Available from: https://doi.org/10.1158/1055-9965.EPI-19-1363
Ref. 398. Edwards DM, et al. (2024) Cancer, 00: 1. DOI: 10.1002/cncr.35340.
Ref. 399. Caswell-Jin JL, et al. (2024) JAMA, 331: 233. DOI: 10.1001/jama.2023.25881.
Ref. 400. Knudsen AB, et al. (2023) JAMA Netw Open, 6: e2344698. DOI: 10.1001/jamanetworkopen.2023.44698.
References 401-450
Ref. 401. Philipson TJ, et al. (2023) BMC Health Serv Res, 23: 829. DOI: 10.1186/s12913-023-09738-4.
Ref. 402. Stone BV, et al. (2024) Eur Urol Oncol, 7: 563. DOI: 10.1016/j.euo.2023.11.020.
Ref. 403. Harper DM, et al. (2024) O G Open, 1: e001. DOI: 10.1097/og9.0000000000000001.
Ref. 404. Doubeni CA, et al. (2018) CA Cancer J Clin, 68: 199. DOI: 10.3322/caac.21452.
Ref. 405. Bodewes FTH, et al. (2022) Breast, 66: 62. DOI: 10.1016/j.breast.2022.09.007.
Ref. 406. United States Preventive Services Taskforce (2023) JAMA, 329: 1290. DOI: 10.1001/jama.2023.4342.
Ref. 407. United States Preventive Services Taskforce (2024) JAMA, 331: 1918. DOI: 10.1001/jama.2024.5534.
Ref. 408. Henderson JT, et al. (2024) JAMA, 331: 1931. DOI: 10.1001/jama.2023.25844.
Ref. 409. United States Preventive Services Taskforce. Draft Recommendation: Breast Cancer: Screening. Accessed: July 5, 2023. Available from: https://www.uspreventiveservicestaskforce.org/uspstf/draft-recommendation/breast-cancer-screening-adults
Ref. 410. Liang Q, et al. (2024) JAMA Oncol, 00: e240827. DOI: 10.1001/jamaoncol.2024.0827.
Ref. 411. Gottschlich A, et al. (2024) Cancer Epidemiol Biomarkers Prev, 33: 904. Available from: https://doi.org/10.1158/1055-9965.EPI-23-1587
Ref. 412. Hussein H, et al. (2023) Radiology, 306: e221785. DOI: 10.1148/radiol.221785.
Ref. 413. Wisse PHA, et al. (2024) Lancet Oncol, 25: 326. DOI: 10.1016/S1470-2045(23)00651-4.
Ref. 414. Scollon S, et al. (2017) J Genet Couns, 26: 387. DOI: 10.1007/s10897-017-0077-8.
Ref. 415. Yeh JM, et al. (2021) Genet Med, 23: 1366. DOI: 10.1038/s41436-021-01124-x.
Ref. 416. Ripperger T, et al. (2017) Am J Med Genet A, 173: 1017. DOI: 10.1002/ajmg.a.38142.
Ref. 417. Brodeur GM, et al. (2017) Clin Cancer Res, 23: e1. Available from: https://doi.org/10.1158/1078-0432.CCR-17-0702
Ref. 418. Greer MC, et al. (2017) Clin Cancer Res, 23: e6. Available from: https://doi.org/10.1158/1078-0432.CCR-17-0515
Ref. 419. Porter CC, et al. (2017) Clin Cancer Res, 23: e14. Available from: https://doi.org/10.1158/1078-0432.CCR-17-0428
Ref. 420. Walsh MF, et al. (2017) Clin Cancer Res, 23: e23. Available from: https://doi.org/10.1158/1078-0432.CCR-17-0465
Ref. 421. Tabori U, et al. (2017) Clin Cancer Res, 23: e32. Available from: https://doi.org/10.1158/1078-0432.CCR-17-0574
Ref. 422. Kratz CP, et al. (2017) Clin Cancer Res, 23: e38. Available from: https://doi.org/10.1158/1078-0432.CCR-17-0408
Ref. 423. Evans DGR, et al. (2017) Clin Cancer Res, 23: e46. Available from: https://doi.org/10.1158/1078-0432.CCR-17-0589
Ref. 424. Evans DGR, et al. (2017) Clin Cancer Res, 23: e54. Available from: https://doi.org/10.1158/1078-0432.CCR-17-0590
Ref. 425. Foulkes WD, et al. (2017) Clin Cancer Res, 23: e62. Available from: https://doi.org/10.1158/1078-0432.CCR-17-0595
Ref. 426. Rednam SP, et al. (2017) Clin Cancer Res, 23: e68. Available from: https://doi.org/10.1158/1078-0432.CCR-17-0547
Ref. 427. Schultz KAP, et al. (2017) Clin Cancer Res, 23: e76. Available from: https://doi.org/10.1158/1078-0432.CCR-17-0629
Ref. 428. Villani A, et al. (2017) Clin Cancer Res, 23: e83. Available from: https://doi.org/10.1158/1078-0432.CCR-17-0631
Ref. 429. Druker H, et al. (2017) Clin Cancer Res, 23: e91. Available from: https://doi.org/10.1158/1078-0432.CCR-17-0834
Ref. 430. Kamihara J, et al. (2017) Clin Cancer Res, 23: e98. Available from: https://doi.org/10.1158/1078-0432.CCR-17-0652
Ref. 431. Achatz MI, et al. (2017) Clin Cancer Res, 23: e107. Available from: https://doi.org/10.1158/1078-0432.CCR-17-0790
Ref. 432. Kalish JM, et al. (2017) Clin Cancer Res, 23: e115. Available from: https://doi.org/10.1158/1078-0432.CCR-17-0710
Ref. 433. Wasserman JD, et al. (2017) Clin Cancer Res, 23: e123. Available from: https://doi.org/10.1158/1078-0432.CCR-17-0548
Ref. 434. Malkin D, et al. (2017) Clin Cancer Res, 23: e133. Available from: https://doi.org/10.1158/1078-0432.CCR-17-2026
Ref. 435. Wang KH, et al. (2019) Front Pediatr, 7: 562. DOI: 10.3389/fped.2019.00562.
Ref. 436. Herzig D, et al. (2017) Dis Colon Rectum, 60: 881. DOI: 10.1097/DCR.0000000000000912.
Ref. 437. Kumamoto T, et al. (2021) Int J Clin Oncol, 26: 2161. DOI: 10.1007/s10147-021-02011-w.
Ref. 438. Ferner RE, et al. (2007) J Med Genet, 44: 81. DOI: 10.1136/jmg.2006.045906.
Ref. 439. Ferner RE, et al. (2013) Handb Clin Neurol, 115: 939. DOI: 10.1016/B978-0-444-52902-2.00053-9.
Ref. 440. Skalet AH, et al. (2018) Ophthalmology, 125: 453. DOI: 10.1016/j.ophtha.2017.09.001.
Ref. 441. Kesserwan C, et al. (2016) Am Soc Clin Oncol Educ Book, 35: 251. DOI: 10.1200/EDBK_160621.
Ref. 442. Fallat ME, et al. (2013) Pediatrics, 131: 620. DOI: 10.1542/peds.2012-3680.
Ref. 443. Sabatino SA, et al. (2023) Prev Chronic Dis, 20: E94. DOI: 10.5888/pcd20.230071.
Ref. 444. Star J, et al. (2023) J Clin Oncol, 41: 4352. DOI: 10.1200/Jco.22.02170.
Ref. 445. Henderson LM, et al. (2024) JAMA Netw Open, 7: e243190. DOI: 10.1001/jamanetworkopen.2024.3190.
Ref. 446. Post AR, et al. (2022) JCO Clin Cancer Inform, 6: e2100158. DOI: 10.1200/CCI.21.00158.
Ref. 447. Kukhareva PV, et al. (2024) JAMA Netw Open, 7: e2415383. DOI: 10.1001/jamanetworkopen.2024.15383.
Ref. 448. Atlas SJ, et al. (2023) JAMA, 330: 1348. DOI: 10.1001/jama.2023.18755.
Ref. 449. HealthIT.gov. USCDI+. Accessed: June 14, 2024. Available from: https://www.healthit.gov/topic/interoperability/uscdi-plus
Ref. 450. Huf SW, et al. (2021) J Gen Intern Med, 36: 1958. DOI: 10.1007/s11606-020-06415-8.
References 451-500
Ref. 451. Mehta SJ, et al. (2024) Clin Gastroenterol Hepatol, 00: 1. DOI: 10.1016/j.cgh.2024.04.003.
Ref. 452. Olmstead T, et al. (2024) Prev Chronic Dis, 21: E30. DOI: 10.5888/pcd21.230266.
Ref. 453. Roche. Roche announces FDA approval of one of the first HPV self-collection solutions in the U.S., expanding access and screening options to help eliminate cervical cancer. Accessed: June 14, 2024. Available from: https://www.roche.com//media/releases/med-cor-2024-05-15
Ref. 454. Winer RL, et al. (2023) JAMA, 330: 1971. DOI: 10.1001/jama.2023.21471.
Ref. 455. Podmore C, et al. (2024) JAMA Netw Open, 7: e245295. DOI: 10.1001/jamanetworkopen.2024.5295.
Ref. 456. Kale S, et al. (2023) Cureus, 15: e43445. DOI: 10.7759/cureus.43445.
Ref. 457. Wangen M, et al. (2023) Cancer Causes Control, 34: 45. DOI: 10.1007/s10552-023-01690-2.
Ref. 458. Nouvini R, et al. (2022) Cancer, 128: 3860. DOI: 10.1002/cncr.34454.
Ref. 459. Chan RJ, et al. (2023) CA Cancer J Clin, 73: 565. DOI: 10.3322/caac.21788.
Ref. 460. Rana T, et al. (2023) Cancer Nurs, 00: 10.1097/NCC.0000000000001222. DOI: 10.1097/NCC.0000000000001222.
Ref. 461. National Cancer Institute. Screen to Save – Colorectal Cancer Screening. Accessed: March 17, 2024. Available from: https://www.cancer.gov/about-nci/organization/crchd/inp/screen-to-save
Ref. 462. Maybee W, et al. (2024) J Cancer Educ, 39: 65. DOI: 10.1007/s13187-023-02376-8.
Ref. 463. National Cancer Institute. Cancer Screening Research Network (CSRN). Accessed: June 14, 2024. Available from: https://prevention.cancer.gov/major-programs/cancer-screening-research-network-csrn
Ref. 464. Lang K, et al. (2023) Lancet Oncol, 24: 936. DOI: 10.1016/S1470-2045(23)00298-X.
Ref. 465. Kang JD, et al. (2021) Eur Radiol, 31: 2422. DOI: 10.1007/s00330-020-07307-5.
Ref. 466. Korfiatis P, et al. (2023) Gastroenterology, 165: 1533. DOI: 10.1053/j.gastro.2023.08.034.
Ref. 467. Cao K, et al. (2023) Nat Med, 29: 3033. DOI: 10.1038/s41591-023-02640-w.
Ref. 468. Farasati Far B (2023) Explor Target Antitumor Ther, 4: 685. DOI: 10.37349/etat.2023.00160.
Ref. 469. Connal S, et al. (2023) J Transl Med, 21: 118. DOI: 10.1186/s12967-023-03960-8.
Ref. 470. Christodoulou E, et al. (2023) NPJ Precis Oncol, 7: 21. DOI: 10.1038/s41698-023-00357-0.
Ref. 471. Fink, J. (2023). Cancer, 129: 1950. DOI: 10.1002/cncr.34882.
Ref. 472. FDA Grants First Marketing Authorization for a DNA Test to Assess Predisposition for Dozens of Cancer Types. Accessed: June 14, 2024. Available from: https://www.fda.gov/news-events/press-announcements/fda-grants-first-marketing-authorization-dna-test-assess-predisposition-dozens-cancer-types
Ref. 473. Barnell EK, et al. (2023) JAMA, 330: 1760. DOI: 10.1001/jama.2023.22231.
Ref. 474. Geneoscopy. FDA Approves ColoSense™ – Geneoscopy’s Noninvasive Multi-target Stool RNA (mt-sRNA) Colorectal Cancer Screening Test – Geneoscopy – Transforming Gastrointestinal Health. Accessed: June 14, 2024. Available from: https://www.geneoscopy.com/fda-approves-colosense-geneoscopys-noninvasive-multi-target-stool-rna-mtrna-colorectal-cancer-screening-test/
Ref. 475. American Association for Cancer Research. An Exosome-based Liquid Biopsy for Non-invasive, Early Detection of Patients with Pancreatic Ductal Adenocarcinoma: A Multicenter and Prospective Study. Accessed: June 14, 2024. Available from: https://www.abstractsonline.com/pp8/#!/20272/presentation/1888
Ref. 476. Xu C, et al. (2024) Gastroenterology, 166: 178. DOI: 10.1053/j.gastro.2023.09.050.
Ref. 477. Foda ZH, et al. (2023) Cancer Discov, 13: 616. Available from: https://doi.org/10.1158/2159-8290.CD-22-0659
Ref. 478. Carr DJ, et al. (2023) JAMA Intern Med, 183: 1144. DOI: 10.1001/jamainternmed.2023.3603.
Ref. 479. Abu Rous F, et al. (2024) JAMA Oncol, 10: 416. DOI: 10.1001/jamaoncol.2023.5778.
Ref. 480. Duenas JAC, et al. (2023) BMC Cancer, 23: 786. DOI: 10.1186/s12885-023-11305-3.
Ref. 481. Koo KC, et al. (2018) BMC Cancer, 18: 468. DOI: 10.1186/s12885-018-4390-x.
Ref. 482. Adashek JJ, et al. (2019) Nat Rev Clin Oncol, 16: 773. DOI: 10.1038/s41571-019-0262-9.
Ref. 483. Kingwell K (2022) Nat Rev Drug Discov, 21: 702. DOI: 10.1038/d41573-022-00144-9.
Ref. 484. Arfe A, et al. (2023) J Natl Cancer Inst, 115: 917. DOI: 10.1093/jnci/djad082.
Ref. 485. Shadbolt C, et al. (2023) JAMA Netw Open, 6: e2250996. DOI: 10.1001/jamanetworkopen.2022.50996.
Ref. 486. Li A, et al. (2020) Cancer, 126: 4838. DOI: 10.1002/cncr.33205.
Ref. 487. Subbiah V (2023) Nat Med, 29: 49. DOI: 10.1038/s41591-022-02160-z.
Ref. 488. Katsoulakis E, et al. (2024) NPJ Digit Med, 7: 77. DOI: 10.1038/s41746-024-01073-0.
Ref. 489. Unger JM, et al. (2024) J Clin Oncol, 42: 2139. DOI: 10.1200/JCO.23.01030.
Ref. 490. National Academies of Sciences, Engineering, and Medicine. Improving Representation in Clinical Trials and Research: Building Research Equity for Women and Underrepresented Groups. Accessed: June 25, 2024. Available from: https://nap.nationalacademies.org/catalog/26479/improving-representation-in-clinical-trials-and-research-building-research-equity
Ref. 491. US Food & Drug Administration. Drug Trials Snapshots: ORSERDU. Accessed: June 14, 2024. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-orserdu
Ref. 492. Swenson WT, et al. (2024) JAMA Oncol, 00: e241690. DOI: 10.1001/jamaoncol.2024.1690.
Ref. 493. Sekar RR, et al. (2024) JAMA Netw Open, 7: e2410162. DOI: 10.1001/jamanetworkopen.2024.10162.
Ref. 494. Miglietta F, et al. (2024) Breast, 75: 103713. DOI: 10.1016/j.breast.2024.103713.
Ref. 495. Khan MMM, et al. (2024) J Gastrointest Surg, 28: 896. DOI: 10.1016/j.gassur.2024.03.027.
Ref. 496. Muffly L, et al. (2022) Blood Adv, 6: 4085. DOI: 10.1182/bloodadvances.2022007197.
Ref. 497. American Association for Cancer Research. AACR Cancer Disparities Progress Report 2022. Accessed: June 30, 2023. Available from: https://cancerprogressreport.aacr.org/wp-content/uploads/sites/2/2022/06/AACR_CDPR_2022.pdf
Ref. 498. Kahn JM, et al. (2022) Cancer, 128: 216. DOI: 10.1002/cncr.33905.
Ref. 499. Allen CJ, et al. (2023) JCO Oncology Practice, 19: 932. DOI: 10.1200/op.23.00159.
Ref. 500. US Food and Drug Administration. Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies. Accessed: Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/diversity-action-plans-improve-enrollment-participants-underrepresented-populations-clinical-studies
References 501-550
Ref. 501. Vanderpool RC, et al. (2024) J Natl Cancer Inst Monogr, 2024: 51. DOI: 10.1093/jncimonographs/lgae016.
Ref. 502. Hamdy FC, et al. (2023) N Engl J Med, 388: 1547. DOI: 10.1056/NEJMoa2214122.
Ref. 503. Levyn H, et al. (2024) JAMA Otolaryngol Head Neck Surg. DOI: 10.1001/jamaoto.2024.1699.
Ref. 504. Lawrence W. History of Surgical Oncology. In: Norton JA, Barie PS, Bollinger RR, Chang AE, Lowry SF, Mulvihill SJ, et al., editors. Surgery. New York, NY: Springer New York; 2008. p 1889.
Ref. 505. Gianfaldoni S, et al. (2017) Open Access Maced J Med Sci, 5: 521. DOI: 10.3889/oamjms.2017.122.
Ref. 506. DeVita VT, Jr., et al. (2008) Cancer Res, 68: 8643. Available from: https://doi.org/10.1158/0008-5472.CAN-07-6611
Ref. 507. Dobashi Y, et al. (2012) Chemotherapy, 1: 2.
Ref. 508. Zhang Y, et al. (2020) Cell Mol Immunol, 17: 807. DOI: 10.1038/s41423-020-0488-6.
Ref. 509. Kim RB, et al. (2024) J Racial Ethn Health Disparities, 00: 10.1007/s40615. DOI: 10.1007/s40615-024-02077-y.
Ref. 510. Tamirisa N, et al. (2023) Ann Surg: 00. DOI: 10.1097/SLA.0000000000006177.
Ref. 511. Chavez-MacGregor M, et al. (2023) J Natl Cancer Inst, 115: 644. DOI: 10.1093/jnci/djad033.
Ref. 512. Dhruva SS, et al. (2024) Health Aff (Millwood), 43: 27. DOI: 10.1377/hlthaff.2023.00466.
Ref. 513. Lubarsky M, et al. (2024) Breast Cancer Res Treat, 206: 509. DOI: 10.1007/s10549-024-07245-6.
Ref. 514. Freeman JQ, et al. (2024) JAMA Netw Open, 7: e249449. DOI: 10.1001/jamanetworkopen.2024.9449.
Ref. 515. Popp R, et al. (2024) Front Oncol, 14: 1327400. DOI: 10.3389/fonc.2024.1327400.
Ref. 516. Beatrici E, et al. (2024) Cancer, 00: 1. DOI: 10.1002/cncr.35328.
Ref. 517. Agudile EP, et al. (2024) J Gastrointest Surg, 00: S1091. DOI: 10.1016/j.gassur.2024.05.015.
Ref. 518. Shen X, et al. (2024) JCO Oncol Pract: OP2300547. DOI: 10.1200/OP.23.00547.
Ref. 519. Frey MK, et al. (2022) Am Soc Clin Oncol Educ Book, 42: 1. DOI: 10.1200/EDBK_350292.
Ref. 520. Burotto M, et al. (2019) Semin Oncol, 46: 83. DOI: 10.1053/j.seminoncol.2019.01.002.
Ref. 521. Topal H, et al. (2022) JAMA Netw Open, 5: e2248147. DOI: 10.1001/jamanetworkopen.2022.48147.
Ref. 522. Son SY, et al. (2022) JAMA Surg, 157: 879. DOI: 10.1001/jamasurg.2022.2749.
Ref. 523. Di Benedetto F, et al. (2023) JAMA Surg, 158: 46. DOI: 10.1001/jamasurg.2022.5697.
Ref. 524. Bartels SAL, et al. (2023) J Clin Oncol, 41: 2159. DOI: 10.1200/Jco.22.01565.
Ref. 525. Gentilini OD, et al. (2023) JAMA Oncol, 9: 1557. DOI: 10.1001/jamaoncol.2023.3759.
Ref. 526. Montagna G, et al. (2024) JAMA Oncol. DOI: 10.1001/jamaoncol.2024.0578.
Ref. 527. de Boniface J, et al. (2024) N Engl J Med, 390: 1163. DOI: 10.1056/NEJMoa2313487.
Ref. 528. Plante M, et al. (2024) N Engl J Med, 390: 819. DOI: 10.1056/NEJMoa2308900.
Ref. 529. Loria A, et al. (2024) JAMA Oncol, 10: 79. DOI: 10.1001/jamaoncol.2023.4845.
Ref. 530. Ghilardi G, et al. (2024) NEJM Evid, 3: EVIDoa2300213. DOI: 10.1056/EVIDoa2300213.
Ref. 531. Wang K, et al. (2021) CA Cancer J Clin, 71: 437. DOI: 10.3322/caac.21689.
Ref. 532. Jagsi R, et al. (2024) J Clin Oncol, 42: 390. DOI: 10.1200/JCO.23.02270.
Ref. 533. Whelan TJ, et al. (2023) N Engl J Med, 389: 612. DOI: 10.1056/NEJMoa2302344.
Ref. 534. Mann GB, et al. (2024) Lancet, 403: 261. DOI: 10.1016/S0140-6736(23)02476-5.
Ref. 535. Siva S, et al. (2024) Lancet Oncol, 25: 308. DOI: 10.1016/S1470-2045(24)00020-2.
Ref. 536. van Moorselaar RJA, et al. (2022) Eur Urol Open Sci, 35: 70. DOI: 10.1016/j.euros.2021.11.004.
Ref. 537. Palma DA, et al. (2020) J Clin Oncol, 38: 2830. DOI: 10.1200/JCO.20.00818.
Ref. 538. Donovan EK, et al. (2024) JAMA Oncol, 00: e241796. DOI: 10.1001/jamaoncol.2024.1796.
Ref. 539. Chinniah S, et al. (2022) Int J Radiat Oncol Biol Phys, 114: 684. DOI: 10.1016/j.ijrobp.2022.07.014.
Ref. 540. Tsai CJ, et al. (2024) Lancet, 403: 171. DOI: 10.1016/S0140-6736(23)01857-3.
Ref. 541. Cho WK, et al. (2024) JAMA Oncol, 10: 737. DOI: 10.1001/jamaoncol.2024.0565.
Ref. 542. Gensheimer MF, et al. (2023) JAMA Oncol, 9: 1525. DOI: 10.1001/jamaoncol.2023.3495.
Ref. 543. American Association for Cancer Research. AACR Cancer Progress Report 2018. Accessed: June 30, 2022. Available from: https://cancerprogressreport.aacr.org/wp-content/uploads/sites/2/2020/09/AACR_CPR_2018.pdf
Ref. 544. Singh S, et al. (2024) Lancet, 403: 2807. DOI: 10.1016/S0140-6736(24)00701-3.
Ref. 545. Oztekin S, et al. (2024) Cancer, 130: 927. DOI: 10.1002/cncr.35125.
Ref. 546. Kasi PM, et al. (2024) J Clin Oncol, 42: 9. DOI: 10.1200/JCO.2024.42.3_suppl.9.
Ref. 547. Giaquinto AN, et al. (2022) CA Cancer J Clin, 72: 524. DOI: 10.3322/caac.21754.
Ref. 548. Turner NC, et al. (2023) N Engl J Med, 388: 2058. DOI: 10.1056/NEJMoa2214131.
Ref. 549. Sathe C, et al. (2024) Breast Cancer Res Treat, 206: 519. DOI: 10.1007/s10549-024-07337-3.
Ref. 550. Arteaga CL, et al. (2014) Clin Cancer Res, 20: S1. Available from: https://doi.org/10.1158/1078-0432.CCR-14-2123
References 551-600
Ref. 551. Sengupta R, et al. (2019) Clin Cancer Res, 25: 5431. Available from: https://doi.org/10.1158/1078-0432.CCR-19-2655
Ref. 552. Li J, et al. (2018) JAMA, 319: 2486. DOI: 10.1001/jama.2018.7855.
Ref. 553. Dasari A, et al. (2023) Lancet, 402: 41. DOI: 10.1016/S0140-6736(23)00772-9.
Ref. 554. Scott JA, et al. (2024) JCO Oncology Practice, 20: 145. DOI: 10.1200/op.22.00611.
Ref. 555. Roberts TJ, et al. (2023) JAMA Netw Open, 6: e2310809. DOI: 10.1001/jamanetworkopen.2023.10809.
Ref. 556. Lemmon CA, et al. (2023) JCO Precis Oncol, 7: e2200294. DOI: 10.1200/PO.22.00294.
Ref. 557. Drilon A, et al. (2024) N Engl J Med, 390: 118. DOI: 10.1056/NEJMoa2302299.
Ref. 558. Yaeger R, et al. (2023) N Engl J Med, 388: 44. DOI: 10.1056/NEJMoa2212419.
Ref. 559. Amodio V, et al. (2020) Cancer Discov, 10: 1129. Available from: https://doi.org/10.1158/2159-8290.CD-20-0187
Ref. 560. Yaeger R, et al. (2024) Cancer Discov, 14: 982. Available from: https://doi.org/10.1158/2159-8290.CD-24-0217
Ref. 561. Bektas M, et al. (2023) Adv Ther, 40: 3697. DOI: 10.1007/s12325-023-02592-0.
Ref. 562. Gounder M, et al. (2023) N Engl J Med, 388: 898. DOI: 10.1056/NEJMoa2210140.
Ref. 563. Yanada M, et al. (2005) Leukemia, 19: 1345. DOI: 10.1038/sj.leu.2403838.
Ref. 564. Erba HP, et al. (2023) Lancet, 401: 1571. DOI: 10.1016/S0140-6736(23)00464-6.
Ref. 565. Bruedigam C, et al. (2024) Nat Cancer, 5: 47. DOI: 10.1038/s43018-023-00653-5.
Ref. 566. Platzbecker U, et al. (2024) Lancet, 403: 249. DOI: 10.1016/S0140-6736(23)01724-5.
Ref. 567. National Organization for Rare Diseases. Primary Myelofibrosis – Symptoms, Causes, Treatment. Accessed: July 31, 2024. Available from: https://rarediseases.org/rare-diseases/primary-myelofibrosis/
Ref. 568. Verstovsek S, et al. (2023) Lancet, 401: 269. DOI: 10.1016/S0140-6736(22)02036-0.
Ref. 569. Mishra AK, et al. (2022) Diseases, 10: 60. DOI: 10.3390/diseases10030060.
Ref. 570. Kaufmann SHE (2019) Front Immunol, 10: 684. DOI: 10.3389/fimmu.2019.00684.
Ref. 571. Garon EB, et al. (2019) J Clin Oncol, 37: 2518. DOI: 10.1200/Jco.19.00934.
Ref. 572. Pala L, et al. (2022) JAMA Netw Open, 5: e2226252. DOI: 10.1001/jamanetworkopen.2022.26252.
Ref. 573. Mai HQ, et al. (2023) JAMA, 330: 1961. DOI: 10.1001/jama.2023.20181.
Ref. 574. Xu J, et al. (2023) Lancet Oncol, 24: 483. DOI: 10.1016/S1470-2045(23)00108-0.
Ref. 575. Westcott PMK, et al. (2023) Nat Genet, 55: 1686. DOI: 10.1038/s41588-023-01499-4.
Ref. 576. Topalian SL, et al. (2019) JAMA Oncol, 5: 1411. DOI: 10.1001/jamaoncol.2019.2187.
Ref. 577. Schmid P, et al. (2020) N Engl J Med, 382: 810. DOI: 10.1056/NEJMoa1910549.
Ref. 578. Altorki NK, et al. (2021) Lancet Oncol, 22: 824. DOI: 10.1016/S1470-2045(21)00149-2.
Ref. 579. Liu C, et al. (2021) Adv Sci (Weinh), 8: e2004433. DOI: 10.1002/advs.202004433.
Ref. 580. Conlon KC, et al. (2019) J Interferon Cytokine Res, 39: 6. DOI: 10.1089/jir.2018.0019.
Ref. 581. Xue D, et al. (2021) Antib Ther, 4: 123. DOI: 10.1093/abt/tbab014.
Ref. 582. McDermott DF, et al. (2006) Semin Oncol, 33: 583. DOI: 10.1053/j.seminoncol.2006.06.004.
Ref. 583. Mond HG, et al. (1981) Pacing Clin Electrophysiol, 4: 304. DOI: 10.1111/j.1540-8159.1981.tb03699.x.
Ref. 584. Bree KK, et al. (2021) Hematol Oncol Clin North Am, 35: 513. DOI: 10.1016/j.hoc.2021.02.003.
Ref. 585. Boorjian SA, et al. (2021) Lancet Oncol, 22: 107. DOI: 10.1016/S1470-2045(20)30540-4.
Ref. 586. Chamie K, et al. (2022) J Clin Oncol, 40: 4508. DOI: 10.1200/JCO.2022.40.16_suppl.4508.
Ref. 587. Rohaan MW, et al. (2019) Virchows Arch, 474: 449. DOI: 10.1007/s00428-018-2484-0.
Ref. 588. D’Angelo SP, et al. (2024) Lancet, 403: 1460. DOI: 10.1016/S0140-6736(24)00319-2.
Ref. 589. Dana H, et al. (2021) Acta Pharm Sin B, 11: 1129. DOI: 10.1016/j.apsb.2020.10.020.
Ref. 590. Westin JR, et al. (2023) N Engl J Med, 389: 148. DOI: 10.1056/NEJMoa2301665.
Ref. 591. Hamilton MP, et al. (2024) N Engl J Med, 390: 2047. DOI: 10.1056/NEJMoa2401361.
Ref. 592. Ozdemirli M, et al. (2024) N Engl J Med, 390: 2074. DOI: 10.1056/NEJMoa2401530.
Ref. 593. Chesney J, et al. (2022) J Immunother Cancer, 10: e005755. DOI: 10.1136/jitc-2022-005755.
Ref. 594. Medina T, et al. (2023) IOTECH, 20: 100591. DOI: 10.1016/j.iotech.2023.100591.
Ref. 595. Baselga J, et al. (2015) Clin Cancer Res, 21: S1. Available from: https://doi.org/10.1158/1078-0432.CCR-15-1846
Ref. 596. Tian Z, et al. (2021) J Hematol Oncol, 14: 75. DOI: 10.1186/s13045-021-01084-4.
Ref. 597. US Food and Drug Administration. FDA Grants Accelerated Approval to talquetamab-tgvs for Relapsed or Refractory Multiple Myeloma. Accessed: Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-talquetamab-tgvs-relapsed-or-refractory-multiple-myeloma
Ref. 598. Cittolin-Santos GF, et al. (2024) Cancer, 130: 2453. DOI: 10.1002/cncr.35281.
Ref. 599. Ahn MJ, et al. (2023) N Engl J Med, 389: 2063. DOI: 10.1056/NEJMoa2307980.
Ref. 600. Butler E, et al. (2021) CA Cancer J Clin, 71: 315. DOI: 10.3322/caac.21665.
References 601-650
Ref. 601. Helms L, et al. (2023) Pediatrics, 152: e2023061539. DOI: 10.1542/peds.2023-061539.
Ref. 602. Hodder A, et al. (2024) Nat Med: s41591. DOI: 10.1038/s41591-024-03056-w.
Ref. 603. Unger JM, et al. (2016) Am Soc Clin Oncol Educ Book, 35: 185. DOI: 10.1200/EDBK_156686.
Ref. 604. Fashoyin-Aje LA, et al. (2024) JAMA Oncol, 10: 380. DOI: 10.1001/jamaoncol.2023.5781.
Ref. 605. Wyatt KD, et al. (2024) JCO Oncol Pract, 20: 603. DOI: 10.1200/OP.23.00826.
Ref. 606. US Food & Drug Administration. Pediatric Oncology Drug Approvals. Accessed: June 26, 2024. Available from: https://www.fda.gov/about-fda/oncology-center-excellence/pediatric-oncology-drug-approvals
Ref. 607. Laetsch TW, et al. (2023) J Clin Oncol, 41: 1664. DOI: 10.1200/Jco.22.00642.
Ref. 608. Brown PA, et al. (2021) JAMA, 325: 833. DOI: 10.1001/jama.2021.0669.
Ref. 609. Locatelli F, et al. (2021) JAMA, 325: 843. DOI: 10.1001/jama.2021.0987.
Ref. 610. van der Sluis IM, et al. (2023) N Engl J Med, 388: 1572. DOI: 10.1056/NEJMoa2214171.
Ref. 611. Kilburn LB, et al. (2024) Nat Med, 30: 207. DOI: 10.1038/s41591-023-02668-y.
Ref. 612. Majzner RG, et al. (2022) Nature, 603: 934. DOI: 10.1038/s41586-022-04489-4.
Ref. 613. Desai AV, et al. (2022) J Clin Oncol, 40: 4107. DOI: 10.1200/Jco.21.02478.
Ref. 614. Oesterheld J, et al. (2024) J Clin Oncol, 42: 90. DOI: 10.1200/JCO.22.02875.
Ref. 615. Chen AP, et al. (2023) N Engl J Med, 389: 911. DOI: 10.1056/NEJMoa2303383.
Ref. 616. Duke ES, et al. (2023) Clin Cancer Res, 29: 3573. Available from: https://doi.org/10.1158/1078-0432.CCR-23-0459
Ref. 617. Ortiz MV, et al. (2020) JCO Precis Oncol, 4: 341. DOI: 10.1200/po.19.00401.
Ref. 618. Liu X, et al. (2023) JAMA Netw Open, 6: e2251524. DOI: 10.1001/jamanetworkopen.2022.51524.
Ref. 619. Manne S, et al. (2023) BMC Cancer, 23: 664. DOI: 10.1186/s12885-023-11098-5.
Ref. 620. Patel VR, et al. (2023) JAMA Oncol, 9: 1001. DOI: 10.1001/jamaoncol.2023.1180.
Ref. 621. Crist JV, et al. (2013) Psychooncology, 22: 978. DOI: 10.1002/pon.3114.
Ref. 622. Zhang X, et al. (2022) Cancer Nurs, 45: 406. DOI: 10.1097/NCC.0000000000001020.
Ref. 623. American Cancer Society. Cancer Treatment and Survivorship Facts and Figures 2022-2024. Accessed: July 10, 2024. Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/cancer-treatment-and-survivorship-facts-and-figures/2022-cancer-treatment-and-survivorship-fandf-acs.pdf
Ref. 624. Mariean CR, et al. (2023) Cancers (Basel), 15: 5590. DOI: 10.3390/cancers15235590.
Ref. 625. Sun H, et al. (2023) BMJ Support Palliat Care, 13: e129. DOI: 10.1136/bmjspcare-2019-002176.
Ref. 626. Fleming B, et al. (2023) BMJ, 380: e071726. DOI: 10.1136/bmj-2022-071726.
Ref. 627. Kim HJ, et al. (2023) Cancer Nurs, 46: E159. DOI: 10.1097/NCC.0000000000001079.
Ref. 628. Kwan ML, et al. (2022) J Clin Oncol, 40: 1635. DOI: 10.1200/JCO.21.01738.
Ref. 629. Greenlee H, et al. (2022) J Clin Oncol, 40: 1647. DOI: 10.1200/JCO.21.01736.
Ref. 630. Hurria A, et al. (2019) J Am Geriatr Soc, 67: 920. DOI: 10.1111/jgs.15493.
Ref. 631. Kresovich JK, et al. (2023) J Natl Cancer Inst, 115: 1329. DOI: 10.1093/jnci/djad117.
Ref. 632. Kerstens C, et al. (2023) Cancers (Basel), 15: 1215. DOI: 10.3390/cancers15041215.
Ref. 633. R K, et al. (2024) J Cancer Surviv, 18: 84. DOI: 10.1007/s11764-023-01336-x.
Ref. 634. Devarakonda SK, et al. (2023) BMC Womens Health, 23: 153. DOI: 10.1186/s12905-023-02243-0.
Ref. 635. Koehler L, et al. (2023) Gynecol Oncol, 170: 254. DOI: 10.1016/j.ygyno.2023.01.019.
Ref. 636. Gilligan AM, et al. (2018) Am J Med, 131: 1187. DOI: 10.1016/j.amjmed.2018.05.020.
Ref. 637. Herrera CD, et al. (2023) Urol Oncol, 41: 105 e1. DOI: 10.1016/j.urolonc.2022.10.014.
Ref. 638. Ehsan AN, et al. (2023) JAMA Netw Open, 6: e2255388. DOI: 10.1001/jamanetworkopen.2022.55388.
Ref. 639. Yabroff KR, et al. (2022) J Natl Cancer Inst, 114: 863. DOI: 10.1093/jnci/djac044.
Ref. 640. Doherty M, et al. (2021) Support Care Cancer, 29: 5753. DOI: 10.1007/s00520-021-06113-z.
Ref. 641. Hallgren E, et al. (2023) J Cancer Surviv, 17: 1338. DOI: 10.1007/s11764-022-01179-y.
Ref. 642. Andreu Y, et al. (2023) Health Qual Life Outcomes, 21: 44. DOI: 10.1186/s12955-023-02124-y.
Ref. 643. Mohile SG, et al. (2016) Cancer, 122: 2459. DOI: 10.1002/cncr.30053.
Ref. 644. Bullock AF, et al. (2024) Eur J Clin Nutr, 78: 486. DOI: 10.1038/s41430-024-01433-9.
Ref. 645. Ispoglou T, et al. (2024) Clin Nutr, 43: 552. DOI: 10.1016/j.clnu.2024.01.009.
Ref. 646. Rodriguez-Arrastia M, et al. (2021) Int J Environ Res Public Health, 18: 4265. DOI: 10.3390/ijerph18084265.
Ref. 647. Hutchinson AN, et al. (2021) Microorganisms, 9: 1344. DOI: 10.3390/microorganisms9061344.
Ref. 648. Pilleron S, et al. (2023) J Geriatr Oncol, 14: 101519. DOI: 10.1016/j.jgo.2023.101519.
Ref. 649. Zhao J, et al. (2023) J Clin Oncol, 41: 6531. DOI: 10.1200/JCO.2023.41.16_suppl.6531.
Ref. 650. McElfresh JJ, et al. (2021) J Psychosoc Oncol, 39: 509. DOI: 10.1080/07347332.2020.1867690.
References 651-700
Ref. 651. Davies LE, et al. (2020) J Am Med Dir Assoc, 21: 181. DOI: 10.1016/j.jamda.2019.10.022.
Ref. 652. Dhalwani NN, et al. (2017) BMJ Open, 7: e016358. DOI: 10.1136/bmjopen-2017-016358.
Ref. 653. Jensen GL, et al. (2001) Am J Clin Nutr, 74: 201. DOI: 10.1093/ajcn/74.2.201.
Ref. 654. Chang TI, et al. (2020) Sci Rep, 10: 18964. DOI: 10.1038/s41598-020-75888-8.
Ref. 655. Leelakanok N, et al. (2017) J Am Pharm Assoc (2003), 57: 729. DOI: 10.1016/j.japh.2017.06.002.
Ref. 656. Maggiore RJ, et al. (2010) Oncologist, 15: 507. DOI: 10.1634/theoncologist.2009-0290.
Ref. 657. Lu-Yao G, et al. (2020) J Geriatr Oncol, 11: 579. DOI: 10.1016/j.jgo.2020.03.001.
Ref. 658. Ramsdale E, et al. (2022) Oncologist, 27: e580. DOI: 10.1093/oncolo/oyac053.
Ref. 659. Shih YT, et al. (2022) J Natl Cancer Inst, 114: 1020. DOI: 10.1093/jnci/djac064.
Ref. 660. Bradley CJ, et al. (2024) J Cancer Surviv, 18: 499. DOI: 10.1007/s11764-022-01248-2.
Ref. 661. Siegel RL, et al. (2021) CA Cancer J Clin, 71: 7. DOI: 10.3322/caac.21654.
Ref. 662. Armstrong GT, et al. (2014) J Clin Oncol, 32: 1218. DOI: 10.1200/Jco.2013.51.1055.
Ref. 663. Hudson MM, et al. (2013) JAMA, 309: 2371. DOI: 10.1001/jama.2013.6296.
Ref. 664. Meijer AJM, et al. (2022) Cancer, 128: 169. DOI: 10.1002/cncr.33848.
Ref. 665. Schulte F, et al. (2022) JAMA Netw Open, 5: e2227225. DOI: 10.1001/jamanetworkopen.2022.27225.
Ref. 666. Phillips NS, et al. (2023) JAMA Netw Open, 6: e2316077. DOI: 10.1001/jamanetworkopen.2023.16077.
Ref. 667. Kruseova J, et al. (2023) Oncol Lett, 25: 43. DOI: 10.3892/ol.2022.13629.
Ref. 668. Williams AM, et al. (2023) J Natl Cancer Inst, 115: 200. DOI: 10.1093/jnci/djac209.
Ref. 669. Guida JL, et al. (2024) Nat Cancer, 5: 731. DOI: 10.1038/s43018-024-00745-w.
Ref. 670. Chao C, et al. (2020) J Clin Oncol, 38: 3161. DOI: 10.1200/Jco.20.00722.
Ref. 671. Chao C, et al. (2019) JAMA Netw Open, 2: e195536. DOI: 10.1001/jamanetworkopen.2019.5536.
Ref. 672. Bright CJ, et al. (2019) Lancet Oncol, 20: 531. DOI: 10.1016/S1470-2045(18)30903-3.
Ref. 673. van der Meer DJ, et al. (2024) Oncologist, 29: e526. DOI: 10.1093/oncolo/oyad307.
Ref. 674. Sung H, et al. (2022) J Natl Cancer Inst, 114: 1095. DOI: 10.1093/jnci/djac091.
Ref. 675. van der Meer DJ, et al. (2024) ESMO Open, 9: 102203. DOI: 10.1016/j.esmoop.2023.102203.
Ref. 676. Xie J, et al. (2022) Cancer Med, 11: 3508. DOI: 10.1002/cam4.4708.
Ref. 677. Alliance for Fertility Preservation. State Laws & Legislation. Accessed: July 31, 2023. Available from: https://www.allianceforfertilitypreservation.org/state-legislation/
Ref. 678. Riva D, et al. (2002) Neurology, 59: 48. DOI: 10.1212/wnl.59.1.48.
Ref. 679. McGrady ME, et al. (2024) J Clin Oncol, 42: 707. DOI: 10.1200/JCO.23.01465.
Ref. 680. Prasad PK, et al. (2015) J Clin Oncol, 33: 2545. DOI: 10.1200/JCO.2014.57.7528.
Ref. 681. O’Donnell N, et al. (2024) BMJ Open, 14: e082779. DOI: 10.1136/bmjopen-2023-082779.
Ref. 682. Fuemmeler BF, et al. (2002) Clin Psychol Rev, 22: 547. DOI: 10.1016/s0272-7358(01)00120-9.
Ref. 683. Currier JM, et al. (2009) J Trauma Stress, 22: 28. DOI: 10.1002/jts.20382.
Ref. 684. Papini C, et al. (2023) Cancer, 129: 1117. DOI: 10.1002/cncr.34633.
Ref. 685. Hsu TW, et al. (2023) J Clin Oncol, 41: 2054. DOI: 10.1200/Jco.22.01189.
Ref. 686. Ryder-Burbidge C, et al. (2021) Cancers (Basel), 13: 4870. DOI: 10.3390/cancers13194870.
Ref. 687. Berkman AM, et al. (2023) J Natl Cancer Inst, 115: 447. DOI: 10.1093/jnci/djac206.
Ref. 688. Osmani V, et al. (2023) Cancer Med, 12: 18354. DOI: 10.1002/cam4.6435.
Ref. 689. Nathan PC, et al. (2023) J Clin Oncol, 41: 1000. DOI: 10.1200/JCO.22.00572.
Ref. 690. Fauer AJ, et al. (2024) JNCI Cancer Spectr, 8: pkae033. DOI: 10.1093/jncics/pkae033.
Ref. 691. Bhatt NS, et al. (2024) JAMA Netw Open, 7: e2410731. DOI: 10.1001/jamanetworkopen.2024.10731.
Ref. 692. Ruiz S, et al. (2023) Pediatrics, 152: e2022059951. DOI: 10.1542/peds.2022-059951.
Ref. 693. Kyronlahti A, et al. (2023) Cancer Med, 12: 16455. DOI: 10.1002/cam4.6218.
Ref. 694. Nathan PC, et al. (2023) J Clin Oncol., 10;41(5):1000-1010. DOI: 10.1200/JCO.22.00572.
Ref. 695. Di Giuseppe G, et al. (2023) Crit Rev Oncol Hematol, 183: 103914. DOI: 10.1016/j.critrevonc.2023.103914.
Ref. 696. Lu AD, et al. (2021) J Natl Cancer Inst, 113: 997. DOI: 10.1093/jnci/djab013.
Ref. 697. Ryan D, et al. (2021) CMAJ Open, 9: E309. DOI: 10.9778/cmajo.20200134.
Ref. 698. National Cancer Institute. Division of Cancer Control and Population Sciences. Pediatric and Adolescent and Young Adult (AYA) Cancer Survivorship. Accessed: July 31, 2024. Available from: https://cancercontrol.cancer.gov/ocs/special-focus-areas/pediatric-adolescent-and-young-adult-survivorship
Ref. 699. Runco DV, et al. (2021) J Pediatr Hematol Oncol, 43: 301. DOI: 10.1097/MPH.0000000000002246.
Ref. 700. Napartuk M, et al. (2023) Children (Basel), 10: 667. DOI: 10.3390/children10040667.
References 701-750
Ref. 701. Wang M, et al. (2024) J Clin Oncol, 42: 1553. DOI: 10.1200/JCO.23.01260.
Ref. 702. Munsie C, et al. (2022) Support Care Cancer, 30: 8159. DOI: 10.1007/s00520-022-07217-w.
Ref. 703. Zhi X, et al. (2019) Integr Cancer Ther, 18: 1534735419895590. DOI: 10.1177/1534735419895590.
Ref. 704. Vasilopoulou M, et al. (2024) Support Care Cancer, 32: 342. DOI: 10.1007/s00520-024-08516-0.
Ref. 705. Berkman AM, et al. (2023) Cancer, 129: 450. DOI: 10.1002/cncr.34505.
Ref. 706. Centers for Disease Control and Prevention. The Health Consequences of Smoking – 50 Years of Progress: A Report of the Surgeon General. Accessed: July 6, 2024. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24455788
Ref. 707. Nolazco JI, et al. (2023) Front Oncol, 13: 1261041. DOI: 10.3389/fonc.2023.1261041.
Ref. 708. Gibson TM, et al. (2015) Cancer, 121: 4035. DOI: 10.1002/cncr.29609.
Ref. 709. Marjerrison S, et al. (2016) Pediatr Blood Cancer, 63: 1254. DOI: 10.1002/pbc.25943.
Ref. 710. Kaul S, et al. (2016) Cancer, 122: 2895. DOI: 10.1002/cncr.30086.
Ref. 711. National Cancer Institute. Adolescents and Young Adults (AYAs) with Cancer. Accessed: Nov 27, 2021. Available from: https://www.cancer.gov/types/aya
Ref. 712. Waddell O, et al. (2023) BJS Open, 7. DOI: 10.1093/bjsopen/zrad030.
Ref. 713. Giles C, et al. (2019) BMJ, 366: l5120. DOI: 10.1136/bmj.l5120.
Ref. 714. Molenaar CJL, et al. (2023) JAMA Surg, 158: 572. DOI: 10.1001/jamasurg.2023.0198.
Ref. 715. Loewen I, et al. (2021) J Otolaryngol Head Neck Surg, 50: 2. DOI: 10.1186/s40463-020-00486-7.
Ref. 716. Brown JC, et al. (2023) Br J Sports Med, 57: 965. DOI: 10.1136/bjsports-2022-106445.
Ref. 717. Lavery JA, et al. (2023) J Clin Oncol, 41: 4982. DOI: 10.1200/JCO.23.00058.
Ref. 718. Kenfield SA, et al. (2023) J Clin Oncol, 41: 4965. DOI: 10.1200/JCO.23.01528.
Ref. 719. Deng N, et al. (2023) Clin Cancer Res, 29: 4361. Available from: https://doi.org/10.1158/1078-0432.CCR-23-0088
Ref. 720. National Cancer Institute. Virtual Mind–Body Fitness Classes Benefit People with Cancer – NCI. Accessed: June 21, 2024. Available from: https://www.cancer.gov/news-events/cancer-currents-blog/2023/mind-body-fitness-cancer-side-effects
Ref. 721. Soltero EG, et al. (2023) J Cancer Surviv: 10.1007/s11764. DOI: 10.1007/s11764-023-01430-0.
Ref. 722. Buro AW, et al. (2023) Int J Environ Res Public Health, 20: 3355. DOI: 10.3390/ijerph20043355.
Ref. 723. Melis M, et al. (2023) Cancer, 129: 1105. DOI: 10.1002/cncr.34640.
Ref. 724. Melis M, et al. (2023) Cancers (Basel), 15: 3632. DOI: 10.3390/cancers15143632.
Ref. 725. Melis M, et al. (2023) J Cancer Surviv: 10.1007/s11764. DOI: 10.1007/s11764-023-01484-0.
Ref. 726. Morice P, et al. (2012) Lancet, 379: 558. DOI: 10.1016/S0140-6736(11)60829-5.
Ref. 727. Trauchburg A, et al. (2023) Nutrients, 15: 3151. DOI: 10.3390/nu15143151.
Ref. 728. Wang DD, et al. (2022) Public Health Nutr, 26: 381. DOI: 10.1017/S1368980022000659.
Ref. 729. Campbell TM, et al. (2024) Breast Cancer Res Treat, 205: 257. DOI: 10.1007/s10549-024-07266-1.
Ref. 730. Chen G, et al. (2023) Nutrients, 15. DOI: 10.3390/nu15092099.
Ref. 731. Monllor-Tormos A, et al. (2023) Maturitas, 178: 107841. DOI: 10.1016/j.maturitas.2023.107841.
Ref. 732. Castro-Espin C, et al. (2023) BMC Med, 21: 225. DOI: 10.1186/s12916-023-02934-3.
Ref. 733. Pavlidou E, et al. (2023) Med Sci (Basel), 11: 74. DOI: 10.3390/medsci11040074.
Ref. 734. Kenkhuis MF, et al. (2023) Br J Nutr, 130: 114. DOI: 10.1017/S0007114522003051.
Ref. 735. Davis EW, et al. (2023) Nutrients, 15: 275. DOI: 10.3390/nu15020275.
Ref. 736. Price SN, et al. (2023) Cancer, 129: 2385. DOI: 10.1002/cncr.34746.
Ref. 737. Bjurlin MA, et al. (2022) Cancer Epidemiol, 78: 102037. DOI: 10.1016/j.canep.2021.102037.
Ref. 738. Lopez-Olivo MA, et al. (2024) J Cancer Surviv, 18: 1059. DOI: 10.1007/s11764-023-01357-6.
Ref. 739. Lu Y, et al. (2023) Sci Rep, 13: 2745. DOI: 10.1038/s41598-023-27624-1.
Ref. 740. Cottrell-Daniels C, et al. (2024) Am J Prev Med, 66: 1049. DOI: 10.1016/j.amepre.2024.02.004.
Ref. 741. Yingst JM, et al. (2023) Psychooncology, 32: 1147. DOI: 10.1002/pon.6171.
Ref. 742. Shi M, et al. (2023) JAMA Netw Open, 6: e2328328. DOI: 10.1001/jamanetworkopen.2023.28328.
Ref. 743. Radbruch L, et al. (2020) J Pain Symptom Manage, 60: 754. DOI: 10.1016/j.jpainsymman.2020.04.027.
Ref. 744. Morgan B, et al. (2023) Curr Probl Cancer, 47: 101019. DOI: 10.1016/j.currproblcancer.2023.101019.
Ref. 745. Sanders JJ, et al. (2024) J Clin Oncol: JCO2400542. DOI: 10.1200/JCO.24.00542.
Ref. 746. Smith CB, et al. (2017) Am Soc Clin Oncol Educ Book, 37: 714. DOI: 10.1200/EDBK_175474.
Ref. 747. Dans M, et al. (2021) J Natl Compr Canc Netw, 19: 780. DOI: 10.6004/jnccn.2021.0033.
Ref. 748. Liska TM, et al. (2020) Health Qual Life Outcomes, 18: 197. DOI: 10.1186/s12955-020-01448-3.
Ref. 749. Shani P, et al. (2022) Integr Cancer Ther, 21: 15347354221103275. DOI: 10.1177/15347354221103275.
Ref. 750. Smith SK, et al. (2018) Am Soc Clin Oncol Educ Book, 38: 813. DOI: 10.1200/EDBK_201307.
References 751-800
Ref. 751. Flores NJ, et al. (2021) Cureus, 13: e14158. DOI: 10.7759/cureus.14158.
Ref. 752. Steel JL, et al. (2024) Lancet, 403: 1351. DOI: 10.1016/S0140-6736(24)00015-1.
Ref. 753. Fu X, et al. (2022) Front Public Health, 10: 927370. DOI: 10.3389/fpubh.2022.927370.
Ref. 754. Lang-Rollin I, et al. (2018) Dialogues Clin Neurosci, 20: 13. DOI: 10.31887/DCNS.2018.20.1/ilangrollin.
Ref. 755. Gregoire C, et al. (2022) Curr Opin Oncol, 34: 270. DOI: 10.1097/CCO.0000000000000847.
Ref. 756. Dos Santos M, et al. (2020) Cancer, 126: 5328. DOI: 10.1002/cncr.33186.
Ref. 757. Sumalla EC, et al. (2009) Clin Psychol Rev, 29: 24. DOI: 10.1016/j.cpr.2008.09.006.
Ref. 758. Gorin SS, et al. (2017) Ann Behav Med, 51: 532. DOI: 10.1007/s12160-017-9876-2.
Ref. 759. Oluwole SF, et al. (2003) J Am Coll Surg, 196: 180. DOI: 10.1016/s1072-7515(02)01765-9.
Ref. 760. Percac-Lima S, et al. (2016) JAMA Intern Med, 176: 930. DOI: 10.1001/jamainternmed.2016.0841.
Ref. 761. Ritvo PG, et al. (2015) Cancer Epidemiol Biomarkers Prev, 24: 506. Available from: https://doi.org/10.1158/1055-9965.EPI-14-0744
Ref. 762. Percac-Lima S, et al. (2015) Cancer, 121: 1662. DOI: 10.1002/cncr.29236.
Ref. 763. Liang H, et al. (2020) Health Care Manage Rev, 45: 364. DOI: 10.1097/HMR.0000000000000226.
Ref. 764. Edward JS, et al. (2023) JCO Oncol Pract, 19: e696. DOI: 10.1200/OP.22.00665.
Ref. 765. Basch E, et al. (2023) J Clin Oncol, 41: 3724. DOI: 10.1200/jco.23.00903.
Ref. 766. Friends of Cancer Research. Broadening the Definition of Tolerability in Cancer Clinical Trials to Better Measure the Patient Experience. Accessed: July 31, 2023. Available from: https://friendsofcancerresearch.org/wp-content/uploads/Comparative-Tolerability-Whitepaper_FINAL.pdf
Ref. 767. Natori A, et al. (2023) J Clin Oncol, 41: 285. DOI: 10.1200/Jco.22.01038.
Ref. 768. Thanarajasingam G, et al. (2022) Lancet Haematol, 9: e374. DOI: 10.1016/S2352-3026(22)00045-X.
Ref. 769. Hensley A, et al. (2023) J Dr Nurs Pract, 16: 22. DOI: 10.1891/JDNP-2022-0018.
Ref. 770. National Partnership for Women and Families. Paid Leave Could Keep More Than 6 Million Caregivers Connected to the Labor Force by 2030. Accessed: March 26, 2024. Available from: https://nationalpartnership.org/wp-content/uploads/2023/02/paid-leave-caregivers-connected-2030.pdf
Ref. 771. Abazari A, et al. (2023) AMIA Annu Symp Proc, 2023: 243.
Ref. 772. Nightingale CL, et al. (2024) J Natl Cancer Inst, 116: 324. DOI: 10.1093/jnci/djad198.
Ref. 773. Bradley CJ, et al. (2022) J Natl Cancer Inst, 114: 1431. DOI: 10.1093/jnci/djac156.
Ref. 774. Bradley CJ (2019) Semin Oncol Nurs, 35: 333. DOI: 10.1016/j.soncn.2019.06.003.
Ref. 775. Bradley CJ, et al. (2023) J Clin Oncol, 41: 2939. DOI: 10.1200/Jco.22.02537.
Ref. 776. Shi Y, et al. (2024) Support Care Cancer, 32: 146. DOI: 10.1007/s00520-024-08349-x.
Ref. 777. Administration for Community Living. 2022 National Strategy to Support Family Caregivers. Accessed: June 21, 2024. Available from: https://acl.gov/sites/default/files/RAISE_SGRG/NatlStrategyToSupportFamilyCaregivers-2.pdf
Ref. 778. Odom JN, et al. (2023) JAMA Netw Open, 6: e2337250. DOI: 10.1001/jamanetworkopen.2023.37250.
Ref. 779. Flores ER, et al. (2024) Cancer Cell, 42: 1133. DOI: 10.1016/j.ccell.2024.05.017.
Ref. 780. Zhang P, et al. (2023) Med, 4: 147. DOI: 10.1016/j.medj.2022.12.001.
Ref. 781. Unnikrishnan K, et al. (2021) Front Oncol, 11: 733652. DOI: 10.3389/fonc.2021.733652.
Ref. 782. Ashworth JC, et al. (2024) Nat Rev Cancer, 24: 461. DOI: 10.1038/s41568-024-00704-8.
Ref. 783. Schwenck J, et al. (2023) Nat Rev Cancer, 23: 474. DOI: 10.1038/s41568-023-00576-4.
Ref. 784. Kuenzi BM, et al. (2020) Nat Rev Cancer, 20: 233. DOI: 10.1038/s41568-020-0240-7.
Ref. 785. Bargahi N, et al. (2022) Biol Proced Online, 24: 5. DOI: 10.1186/s12575-022-00166-y.
Ref. 786. Siepel FJ, et al. (2021) Current Robotics Reports, 2: 73. DOI: 10.1007/s43154-020-00042-1.
Ref. 787. Tan X, et al. (2021) Cell, 184: 881. DOI: 10.1016/j.cell.2021.01.017.
Ref. 788. Keshari KR, et al. (2024) Cancer Cell, 42: 1138. DOI: 10.1016/j.ccell.2024.04.013.
Ref. 789. Jaffray DA, et al. Radiation Therapy for Cancer. In: Gelband H, Jha P, Sankaranarayanan R, Horton S, editors. Cancer: Disease Control Priorities, Third Edition (Volume 3). Washington (DC) 2015.
Ref. 790. Kramer K, et al. (2014) Pediatr Blood Cancer, 61: 1590. DOI: 10.1002/pbc.25080.
Ref. 791. Choi JY (2023) Brain Tumor Res Treat, 11: 28. DOI: 10.14791/btrt.2022.0046.
Ref. 792. Ostrom QT, et al. (2023) Neuro Oncol, 25: iv1. DOI: 10.1093/neuonc/noad149.
Ref. 793. Yang S, et al. (2020) Int J Biol Sci, 16: 1767. DOI: 10.7150/ijbs.41105.
Ref. 794. Bailey K, et al. (2019) J Neurooncol, 143: 101. DOI: 10.1007/s11060-019-03139-6.
Ref. 795. Tringale KR, et al. (2023) J Neurooncol, 162: 69. DOI: 10.1007/s11060-022-04235-w.
Ref. 796. Bodei L, et al. (2022) Nat Rev Clin Oncol, 19: 534. DOI: 10.1038/s41571-022-00652-y.
Ref. 797. Lapi SE, et al. (2024) Lancet Oncol, 25: e236. DOI: 10.1016/S1470-2045(24)00030-5.
Ref. 798. Duan H, et al. (2022) Nanotheranostics, 6: 103. DOI: 10.7150/ntno.64141.
Ref. 799. Aboagye EO, et al. (2023) CA Cancer J Clin, 73: 255. DOI: 10.3322/caac.21768.
Ref. 800. Eapen RS, et al. (2024) Eur Urol, 85: 217. DOI: 10.1016/j.eururo.2023.08.026.
References 801-850
Ref. 801. Korde A, et al. (2024) EJNMMI Radiopharm Chem, 9: 2. DOI: 10.1186/s41181-023-00230-2.
Ref. 802. Giammarile F, et al. (2024) Lancet Oncol, 25: e260. DOI: 10.1016/S1470-2045(24)00041-X.
Ref. 803. Scott AM, et al. (2024) Lancet Oncol, 25: e250. DOI: 10.1016/S1470-2045(24)00037-8.
Ref. 804. Farwell MD, et al. (2014) Cancer, 120: 3433. DOI: 10.1002/cncr.28860.
Ref. 805. Alberts I, et al. (2023) Cancer Imaging, 23: 28. DOI: 10.1186/s40644-023-00540-3.
Ref. 806. Daube-Witherspoon ME, et al. (2022) Br J Radiol, 95: 20220357. DOI: 10.1259/bjr.20220357.
Ref. 807. Nadig V, et al. (2022) Eur J Nucl Med Mol Imaging, 49: 445. DOI: 10.1007/s00259-021-05536-4.
Ref. 808. Cherry SR, et al. (2018) J Nucl Med, 59: 3. DOI: 10.2967/jnumed.116.184028.
Ref. 809. Beyer T, et al. (2000) J Nucl Med, 41: 1369. PMID: 10945530
Ref. 810. Shao Y, et al. (1997) Phys Med Biol, 42: 1965. DOI: 10.1088/0031-9155/42/10/010.
Ref. 811. Judenhofer MS, et al. (2008) Nat Med, 14: 459. DOI: 10.1038/nm1700.
Ref. 812. Sjoholm T, et al. (2022) Cancer Imaging, 22: 76. DOI: 10.1186/s40644-022-00513-y.
Ref. 813. Sandgren K, et al. (2023) Nucl Med Commun, 44: 997. DOI: 10.1097/MNM.0000000000001743.
Ref. 814. Lombardi G, et al. (2022) Br J Radiol, 95: 20211018. DOI: 10.1259/bjr.20211018.
Ref. 815. Darr C, et al. (2023) Eur Urol Open Sci, 54: 28. DOI: 10.1016/j.euros.2023.05.017.
Ref. 816. Eddy RL, et al. (2024) J Vis Exp, 206: e66257. DOI: 10.3791/66257.
Ref. 817. Kaggie JD, et al. (2022) Neuroimage, 257: 119284. DOI: 10.1016/j.neuroimage.2022.119284.
Ref. 818. Brindle KM (2024) npj Imaging, 2: 1. DOI: 10.1038/s44303-023-00004-0.
Ref. 819. Mori Y, et al. (2023) Radiology, 306: e220749. DOI: 10.1148/radiol.220749.
Ref. 820. Altmann A, et al. (2021) J Nucl Med, 62: 160. DOI: 10.2967/jnumed.120.244806.
Ref. 821. Koerber SA, et al. (2023) J Nucl Med, 64: 1712. DOI: 10.2967/jnumed.123.266046.
Ref. 822. Chandekar KR, et al. (2023) Diagnostics (Basel), 13: 2018. DOI: 10.3390/diagnostics13122018.
Ref. 823. Kratochwil C, et al. (2019) J Nucl Med, 60: 801. DOI: 10.2967/jnumed.119.227967.
Ref. 824. Arroyo A, et al. (2024) Methods Mol Biol, 2729: 117. DOI: 10.1007/978-1-0716-3499-8_8.
Ref. 825. Xiu MX, et al. (2020) Onco Targets Ther, 13: 3881. DOI: 10.2147/OTT.S244860.
Ref. 826. Korsen JA, et al. (2022) J Nucl Med, 63: 1401. DOI: 10.2967/jnumed.121.263221.
Ref. 827. Tendler S, et al. (2024) medRxiv: 2024.01.10.24301109. DOI: 10.1101/2024.01.10.24301109.
Ref. 828. Rudin CM, et al. (2023) J Hematol Oncol, 16: 66. DOI: 10.1186/s13045-023-01464-y.
Ref. 829. Yao J, et al. (2022) Oncologist, 27: 940. DOI: 10.1093/oncolo/oyac161.
Ref. 830. Liao S, et al. (2023) iScience, 26: 107277. DOI: 10.1016/j.isci.2023.107277.
Ref. 831. Congress.gov. H.R.2882 – 118th Congress (2023-2024): Further Consolidated Appropriations Act, 2024. Accessed: July 12, 2024. Available from: https://www.congress.gov/bill/118th-congress/house-bill/2882
Ref. 832. National Cancer Institute. Fiscal Year 2024 Appropriation Brings Clarity and Difficult Choices. Accessed: July 12, 2024. Available from: https://www.cancer.gov/grants-training/nci-bottom-line-blog/2024/nci-fy-2024-appropriation-brings-clarity-and-difficult-choices
Ref. 833. National Institutes of Health. Grants & Funding. Accessed: July 12, 2024. Available from: https://www.nih.gov/grants-funding
Ref. 834. National Institutes of Health. National Cancer Institute. Accessed: July 12, 2024. Available from: https://www.nih.gov/about-nih/what-we-do/nih-almanac/national-cancer-institute-nci
Ref. 835. National Institutes of Health. Advanced Research Projects Agency for Health (ARPA-H). Accessed: July 12, 2024. Available from: https://www.nih.gov/arpa-h
Ref. 836. US Food & Drug Administration. Oncology Center of Excellence. Accessed: July 12, 2024. Available from: https://www.fda.gov/about-fda/fda-organization/oncology-center-excellence
Ref. 837. US Food & Drug Administration. Center for Tobacco Products. Accessed: July 12, 2024. Available from: https://www.fda.gov/about-fda/fda-organization/center-tobacco-products
Ref. 838. Agency for Healthcare Research and Quality. Research Training and Education. Accessed: August 2, 2024. Available from: https://www.ahrq.gov/funding/training-grants/index.html
Ref. 839. Centers for Disease Control and Prevention. About the Division of Cancer Prevention and Control | National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP). Accessed: July 12, 2024. Available from: https://www.cdc.gov/nccdphp/divisions-offices/about-the-division-of-cancer-prevention-and-control.html
Ref. 840. North American Association of Central Cancer Registries. About NAACCR. Accessed: Available from: https://www.naaccr.org/about-naaccr/
Ref. 841. Centers for Disease Control and Prevention. About the Public Health Infrastructure Center. Accessed: August 2, 2024. Available from: https://www.cdc.gov/infrastructure/index.html
Ref. 842. Loomans-Kropp HA, et al. (2019) J Cancer Epidemiol, 2019: 9841295. DOI: 10.1155/2019/9841295.
Ref. 843. United For Medical Research. NIH’s Role in Sustaining the U.S. Economy. Every State Benefits. Accessed: July 12, 2024. Available from: https://www.unitedformedicalresearch.org/wp-content/uploads/2024/03/UMR-NIHs-Role-in-Sustaining-the-US-Economy-2024-Update.pdf
Ref. 844. University of Illinois Chicago. A National Security Case for Public Health Infrastructure and Universal Healthcare | School of Public Health. Accessed: July 12, 2024. Available from: https://publichealth.uic.edu/news-stories/a-national-security-case-for-public-health-infrastructure-and-universal-healthcare/
Ref. 845. Wherry EJ, et al. (2021) Clin Cancer Res, 27: 2136. Available from: https://doi.org/10.1158/1078-0432.CCR-21-0079
Ref. 846. National Institutes of Health. Decades in the Making: mRNA COVID-19 Vaccines. Accessed: July 12, 2024. Available from: https://covid19.nih.gov/nih-strategic-response-covid-19/decades-making-mrna-covid-19-vaccines
Ref. 847. Damijan JP, et al. (2022) Vaccines (Basel), 10: 678. DOI: 10.3390/vaccines10050678.
Ref. 848. Scientific American. Vaccination Dramatically Lowers Long COVID Risk. Accessed: July 12, 2024. Available from: https://www.scientificamerican.com/article/vaccination-dramatically-lowers-long-covid-risk/
Ref. 849. The White House. Budget of the U.S. Government FISCAL YEAR 2025. Accessed: July 12, 2024. Available from: https://www.whitehouse.gov/wp-content/uploads/2024/03/budget_fy2025.pdf
Ref. 850. National Cancer Institute. Cancer Moonshot. Accessed: July 12, 2024. Available from: https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative
References 851-900
Ref. 851. Congressional Research Service. National Institutes of Health (NIH) Funding: FY1996-FY2023. Accessed: July 12, 2024. Available from: https://crsreports.congress.gov/product/pdf/R/R43341/45
Ref. 852. Congress.gov. H.R.3746 – 118th Congress (2023-2024): Fiscal Responsibility Act of 2023. Accessed: July 12, 2024. Available from: https://www.congress.gov/bill/118th-congress/house-bill/3746/summary/00
Ref. 853. Freeman RB, et al. (2014) Nature, 513: 305. DOI: 10.1038/513305a.
Ref. 854. AlShebli BK, et al. (2018) Nat Commun, 9: 5163. DOI: 10.1038/s41467-018-07634-8.
Ref. 855. Pittman P, et al. (2021) Med Care, 59: S405. DOI: 10.1097/MLR.0000000000001609.
Ref. 856. Jackson CS, et al. (2014) Public Health Rep, 129 Suppl 2: 57. DOI: 10.1177/00333549141291S211.
Ref. 857. US National Science Foundation. About NSF. Accessed: July 12, 2024. Available from: https://new.nsf.gov/about
Ref. 858. US National Science Foundation. Directorate for STEM Education (EDU). Accessed: July 12, 2024. Available from: https://new.nsf.gov/edu
Ref. 859. US National Science Foundation. About Equity for Excellence in STEM (EES). Accessed: July 12, 2024. Available from: https://www.nsf.gov/edu/ees/about.jsp
Ref. 860. US National Science Foundation. CHIPS and Science. Accessed: July 12, 2024. Available from: https://new.nsf.gov/chips
Ref. 861. The White House. FACT SHEET: CHIPS and Science Act Will Lower Costs, Create Jobs, Strengthen Supply Chains, and Counter China | The White House. Accessed: March 30, 2024. Available from: https://www.whitehouse.gov/briefing-room/statements-releases/2022/08/09/fact-sheet-chips-and-science-act-will-lower-costs-create-jobs-strengthen-supply-chains-and-counter-china/
Ref. 862. Brookings. The Bold Vision of the CHIPS and Science Act Isn’t Getting the Funding it Needs. Accessed: July 12, 2024. Available from: https://www.brookings.edu/articles/the-bold-vision-of-the-chips-and-science-act-isnt-getting-the-funding-it-needs/
Ref. 863. National Institutes of Health. Ending Structural Racism. UNITE. Accessed: March 17, 2024. Available from: https://www.nih.gov/ending-structural-racism/unite
Ref. 864. National Institutes of Health. Office of the Director. Chief Officer for Scientific Workforce Diversity. Act. Accessed: July 12, 2024. Available from: https://diversity.nih.gov/act
Ref. 865. National Institutes of Health. NIH Institute/Center Research Training and Career Development Information. Accessed: July 12, 2024. Available from: https://researchtraining.nih.gov/ic-table
Ref. 866. National Cancer Institute. Funding for Cancer Training. Accessed: July 12, 2024. Available from: https://www.cancer.gov/grants-training/training/funding
Ref. 867. National Institutes of Health. Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional). Accessed: July 12, 2024. Available from: https://grants.nih.gov/grants/guide/pa-files/PAR-21-321.html
Ref. 868. Li CI, et al. (2024) J Natl Cancer Inst, 00: djae100. DOI: 10.1093/jnci/djae100.
Ref. 869. National Cancer Institute. CRCHD Diversity Training. Accessed: July 12, 2024. Available from: https://www.cancer.gov/about-nci/organization/crchd/diversity-training
Ref. 870. Ly DP, et al. (2022) Ann Intern Med, 175: 873. DOI: 10.7326/M21-4312.
Ref. 871. Pereira RI, et al. (2024) Lancet, 403: 332. DOI: 10.1016/S0140-6736(23)02700-9.
Ref. 872. National Science Foundation. Graduate Enrollment in Science, Engineering, and Health Continues to Increase among Foreign Nationals, while Postdoctoral Appointment Trends Vary across Fields. Accessed: July 12, 2024. Available from: https://ncses.nsf.gov/pubs/nsf24320
Ref. 873. National Institutes of Health. NIH Advisory Committee To The Director Working Group On Re-Envisioning NIH-Supported Postdoctoral Training. Accessed: July 12, 2024. Available from: https://www.acd.od.nih.gov/documents/presentations/12152023_Postdoc_Working_Group_Report.pdf
Ref. 874. Science Magazine. Fewer U.S. Scientists Are Pursuing Postdoc Positions, New Data Show. Accessed: Available from: https://www.science.org/content/article/fewer-u-s-scientists-are-pursuing-postdoc-positions-new-data-show
Ref. 875. National Institutes of Health. ACD Working Group on Re-envisioning NIH-Supported Postdoctoral Training. Accessed: July 12, 2024. Available from: https://www.acd.od.nih.gov/working-groups/postdocs.html
Ref. 876. Congressional Research Service. Medicare Graduate Medical Education Payments: An Overview. Accessed: March 17, 2024. Available from: https://crsreports.congress.gov/product/pdf/IF/IF10960
Ref. 877. American Medical Association. 2023 Compendium of Graduate Medical Education Initiatives Report. Accessed: March 17, 2024. Available from: https://www.ama-assn.org/system/files/2023-gme-compendium-report.pdf
Ref. 878. Congressional Research Service. Federal Support for Graduate Medical Education: An Overview. Accessed: August 2, 2024. Available from: https://crsreports.congress.gov/product/pdf/R/R44376
Ref. 879. Rains J, et al. (2023) JAMA, 330: 968. DOI: 10.1001/jama.2023.14452.
Ref. 880. National Cancer Institute. Cancer Prevention Fellowship Program. Accessed: July 12, 2024. Available from: https://cpfp.cancer.gov/home
Ref. 881. MD Anderson Cancer Center. Cancer Prevention Research Training Program. Accessed: July 12, 2024. Available from: https://www.mdanderson.org/research/departments-labs-institutes/programs-centers/cancer-prevention-research-training-program.html
Ref. 882. Robert H. Lurie Comprehensive Cancer Center of Northwestern University. Cancer Prevention & Control. Accessed: July 12, 2024. Available from: https://www.cancer.northwestern.edu/research/education-training/prevention/index.html
Ref. 883. VCU Massey Comprehensive Cancer Center. Cancer Prevention & Control Program. Accessed: July 12, 2024. Available from: http://www.masseycancercenter.org/research/research-programs/cancer-prevention-and-control
Ref. 884. Yale Cancer Center. Yale Cancer Prevention and Control (CPC) Training Program. Accessed: July 12, 2024. Available from: https://www.yalecancercenter.org/research/education/graduate/cpctraining/
Ref. 885. US Department of Health and Human Services. HHS Announces Health Resources and Services Administration-Funded Health Centers Partnering With National Cancer Institute-Designated Cancer Centers to Improve Equity in Cancer Screening. Accessed: July 12, 2024. Available from: https://www.hhs.gov/about/news/2022/09/23/hhs-announces-health-resources-services-administration-funded-health-centers-partnering-with-national-cancer-institute-designated-cancer-centers-improve-equity-cancer-screening.html
Ref. 886. Goldberg KB, et al. (2018) Experimental Biology and Medicine, 243: 308. DOI: 10.1177/1535370217740861.
Ref. 887. Pittell H, et al. (2023) JAMA Netw Open, 6: e2322515. DOI: 10.1001/jamanetworkopen.2023.22515.
Ref. 888. NIH Office of Research on Women’s Health. Review of the Literature: Primary Barriers and Facilitators to Participation in Clinical Research. Accessed: March 17, 2024. Available from: https://orwh.od.nih.gov/sites/orwh/files/docs/orwh_outreach_toolkit_litreview.pdf
Ref. 889. Underhill C, et al. (2024) JAMA Oncol, 10: 526. DOI: 10.1001/jamaoncol.2023.6565.
Ref. 890. US Food & Drug Administration. Decentralized Clinical Trials for Drugs, Biological Products, and Devices. Guidance for Industry, Investigators, and Other Stakeholders. Accessed: July 12, 2024. Available from: https://www.fda.gov/media/167696/download
Ref. 891. US Food & Drug Administration. OCE Programs and Projects Overview. Accessed: July 12, 2024. Available from: https://www.fda.gov/about-fda/oncology-center-excellence/oce-programs-and-projects-overview
Ref. 892. US Food & Drug Administration. Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies Guidance for Industry. Accessed: July 12, 2024. Available from: https://www.fda.gov/media/179593/download
Ref. 893. US Food and Drug Administration. Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials Guidance for Industry. Accessed: July 5, 2023. Available from: https://www.fda.gov/media/157635/download
Ref. 894. Kim ES, et al. (2021) Clin Cancer Res, 27: 2394. Available from: https://doi.org/10.1158/1078-0432.CCR-20-3852
Ref. 895. US Food & Drug Administration. Cancer Clinical Trial Eligibility Criteria: Washout Periods and Concomitant Medications Guidance for Industry, IRBs, and Clinical Investigators. Accessed: July 12, 2024. Available from: https://www.fda.gov/media/178016/download
Ref. 896. US Food & Drug Administration. Cancer Clinical Trial Eligibility Criteria: Laboratory Values Guidance for Industry, IRBs, and Clinical Investigators. Accessed: July 12, 2024. Available from: https://www.fda.gov/media/178013/download
Ref. 897. US Food & Drug Administration. Cancer Clinical Trial Eligibility Criteria: Performance Status Guidance for Industry, IRBs, and Clinical Investigators. Accessed: July 12, 2024. Available from: https://www.fda.gov/media/178018/download
Ref. 898. The Cancer Letter. ODAC Unanimously Upholds MRD As Early Endpoint Across All Settings in Multiple Myeloma. Accessed: July 12, 2024. Available from: https://cancerletter.com/regulatory-news/20240426_1/
Ref. 899. Merino M, et al. (2023) J Clin Oncol, 41: 2706. DOI: 10.1200/Jco.23.00225.
Ref. 900. Rodriguez LR, et al. (2024) Clin Cancer Res. Available from: https://doi.org/10.1158/1078-0432.CCR-24-0919
References 901-965
Ref. 901. Fourie Zirkelbach J, et al. (2022) J Clin Oncol, 40: 3489. DOI: 10.1200/JCO.22.00371.
Ref. 902. US Food and Drug Administration. Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases. Accessed: July 5, 2023. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/optimizing-dosage-human-prescription-drugs-and-biological-products-treatment-oncologic-diseases
Ref. 903. American Association for Cancer Research. FDA-AACR Workshop: How Much is Enough? Trial Designs for Treatment Regimens with Multiple Phases. Accessed: July 12, 2024. Available from: https://www.aacr.org/professionals/policy-and-advocacy/regulatory-science-and-policy/events/fda-aacr-workshop-how-much-is-enough-trial-designs-for-treatment-regimens-with-multiple-phases/
Ref. 904. American Association for Cancer Research. FDA-AACR Public Workshop: Optimizing Dosages for Oncology Drug Products. Accessed: July 12, 2024. Available from: https://www.aacr.org/professionals/policy-and-advocacy/regulatory-science-and-policy/events/fda-aacr-workshop-optimizing-dosages-for-oncology-drug-products/
Ref. 905. National Comprehensive Cancer Network. New Survey from NCCN Finds Cancer Drug Shortage Management Remains a Moving Target, Impacting Clinical Trials. Accessed: July 31, 2024. Available from: https://www.nccn.org/home/news/newsdetails?NewsId=4620
Ref. 906. Medscape. ‘Nothing Rivaled This’: Navigating the Cancer Drug Shortage. Accessed: July 12, 2024. Available from: https://www.medscape.com/viewarticle/nothing-rivaled-this-navigating-oncology-drug-shortage-2024a10006fe
Ref. 907. Breastcancer.org. Chemotherapy Drug Shortage: What You Need to Know. Accessed: July 12. Available from: https://www.breastcancer.org/news/chemotherapy-drug-shortage
Ref. 908. American Cancer Society Cancer Action Network. Survivor Views: Drug Shortages, Telehealth, & Biomarker Testing. Accessed: July 31, 2024. Available from: https://www.fightcancer.org/sites/default/files/docs/survey_drug_shortages_biomarkers_final_3.19.pdf
Ref. 909. US Food & Drug Administration. Drug Shortages. Accessed: July 12, 2024. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages
Ref. 910. The White House. Strengthening the supply chain for cancer drugs. Accessed: July 12, 2024. Available from: https://www.whitehouse.gov/ostp/news-updates/2023/09/12/strengthening-the-supply-chain-for-cancer-drugs/
Ref. 911. United States Senate Committee on Finance. Senate Finance Committee Discussion Draft: Preventing & Mitigating Generic Drug Shortages. Accessed: July 12, 2024. Available from: https://www.finance.senate.gov/imo/media/doc/050124_sfc_drug_shortages_discussion_draft_one_pager.pdf
Ref. 912. Centers for Medicare & Medicaid Services. FY 2025 Hospital Inpatient Prospective Payment System (IPPS) and Long-Term Care Hospital Prospective Payment System (LTCH PPS) Proposed Rule – CMS-1808-P Fact Sheet. Accessed: July 12, 2024. Available from: https://www.cms.gov/newsroom/fact-sheets/fy-2025-hospital-inpatient-prospective-payment-system-ipps-and-long-term-care-hospital-prospective
Ref. 913. Centers for Medicare & Medicaid Services. CMS Releases Revised Guidance for Medicare Prescription Drug Inflation Rebate Program. Accessed: July 12, 2024. Available from: https://www.cms.gov/newsroom/press-releases/cms-releases-revised-guidance-medicare-prescription-drug-inflation-rebate-program
Ref. 914. Pingali C, et al. (2022) MMWR Morb Mortal Wkly Rep, 71: 1101. DOI: 10.15585/mmwr.mm7135a1.
Ref. 915. US Food & Drug Administration. FDA Roundup: May 17, 2024. Accessed: July 12, 2024. Available from: https://www.fda.gov/news-events/press-announcements/fda-roundup-may-17-2024
Ref. 916. National Cancer Institute. Rural-Urban Disparities in Cancer. Accessed: July 12, 2024. Available from: https://gis.cancer.gov/mapstory/rural-urban/index.html
Ref. 917. Champion VL, et al. (2023) JAMA Netw Open, 6: e2311004. DOI: 10.1001/jamanetworkopen.2023.11004.
Ref. 918. Congress.gov. Text – S.1840 – 118th Congress (2023-2024): Screening for Communities to Receive Early and Equitable Needed Services for Cancer Act of 2023. Accessed: July 12, 2024. Available from: https://www.congress.gov/bill/118th-congress/senate-bill/1840/text
Ref. 919. Centers for Disease Control and Prevention. Meeting the Needs of Special Populations. Accessed: July 12, 2024. Available from: https://www.cdc.gov/breast-cervical-cancer-screening/success/special-populations.html
Ref. 920. Centers for Disease Control and Prevention. Jewish Women and BRCA Gene Mutations. Bring Your Brave Campaign. Accessed: July 12, 2024. Available from: https://www.cdc.gov/bring-your-brave/hereditary-breast-cancer/jewish-women-brca.html
Ref. 921. US Environmental Protection Agency. EPA Efforts to Reduce Exposure to Carcinogens and Prevent Cancer. Accessed: March 17, 2024. Available from: https://www.epa.gov/environmental-topics/epa-efforts-reduce-exposure-carcinogens-and-prevent-cancer
Ref. 922. US Environmental Protection Agency. Clean School Bus Program. Accessed: July 12, 2024. Available from: https://www.epa.gov/cleanschoolbus
Ref. 923. US Environmental Protection Agency. Emergency Response. Accessed: July 12, 2024. Available from: https://www.epa.gov/emergency-response
Ref. 924. Wang TW, et al. (2019) MMWR Surveill Summ, 68: 1. DOI: 10.15585/mmwr.ss6812a1.
Ref. 925. Le TT, et al. (2021) Tob Control, 00: tobaccocontrol. DOI: 10.1136/tobaccocontrol-2020-056256.
Ref. 926. US Food & Drug Administration. FDA Proposes Rules Prohibiting Menthol Cigarettes and Flavored Cigars to Prevent Youth Initiation, Significantly Reduce Tobacco-Related Disease and Death. Accessed: July 12, 2024. Available from: https://www.fda.gov/news-events/press-announcements/fda-proposes-rules-prohibiting-menthol-cigarettes-and-flavored-cigars-prevent-youth-initiation
Ref. 927. US Department of Health and Human Services. Secretary Becerra Statement on the Proposed Menthol Cigarette Rule. Accessed: July 12, 2024. Available from: https://www.hhs.gov/about/news/2024/04/26/secretary-becerra-statement-proposed-menthol-cigarette-rule.html
Ref. 928. US Food & Drug Administration. Joint Federal Operation Results in Seizure of More Than $18 Million in Illegal E-Cigarettes. Accessed: July 12, 2024. Available from: https://www.fda.gov/news-events/press-announcements/joint-federal-operation-results-seizure-more-18-million-illegal-e-cigarettes
Ref. 929. US Food & Drug Administration. FDA Seeks $20K+ Fines Against Retailers Selling Unauthorized Youth-Appealing E-Cigarettes. Accessed: July 12, 2024. Available from: https://www.fda.gov/tobacco-products/ctp-newsroom/fda-seeks-20k-fines-against-retailers-selling-unauthorized-youth-appealing-e-cigarettes
Ref. 930. US Food & Drug Administration. Justice Department and FDA Announce Federal Multi-Agency Task Force to Curb the Distribution and Sale of Illegal E-Cigarettes. Accessed: July 12, 2024. Available from: https://www.fda.gov/news-events/press-announcements/justice-department-and-fda-announce-federal-multi-agency-task-force-curb-distribution-and-sale
Ref. 931. The New York Times. F.D.A. Aims to Cut Down on Smoking by Slashing Nicotine Levels in Cigarettes. Accessed: July 12, 2024. Available from: https://www.nytimes.com/2022/06/21/health/fda-nicotine-cigarettes.html
Ref. 932. Federal Register. Tobacco Product Standard for Nicotine Level of Combusted Cigarettes. Accessed: July 12, 2024. Available from: https://www.federalregister.gov/documents/2018/03/16/2018-05345/tobacco-product-standard-for-nicotine-level-of-combusted-cigarettes
Ref. 933. Donny EC, et al. (2022) Int J Drug Policy, 99: 103436. DOI: 10.1016/j.drugpo.2021.103436.
Ref. 934. Apelberg BJ, et al. (2018) N Engl J Med, 378: 1725. DOI: 10.1056/NEJMsr1714617.
Ref. 935. Cronin KA, et al. (2022) Cancer, 128: 4251. DOI: 10.1002/cncr.34479.
Ref. 936. National Cancer Institute. Cancer Among Adolescents and Young Adults (AYAs) – Cancer Stat Facts. Accessed: Jul 5, 2023. Available from: https://seer.cancer.gov/statfacts/html/aya.html
Ref. 937. US Government Accountability Office. Pediatric Cancer Studies: Early Results of the Research to Accelerate Cures and Equity for Children Act. Accessed: July 12, 2024. Available from: https://www.gao.gov/assets/gao-23-105947.pdf
Ref. 938. Energy and Commerce. Health Subcommittee Markup Recap: E&C Advances Legislation to Strengthen America’s Health Care System. Accessed: July 12, 2024. Available from: https://energycommerce.house.gov/posts/health-subcommittee-markup-recap-e-and-c-advances-legislation-to-strengthen-america-s-health-care-system
Ref. 939. National Institutes of Health. Gabriella Miller Kids First Pediatric Research (Kids First). Accessed: July 5, 2023. Available from: https://www.commonfund.nih.gov/KidsFirst
Ref. 940. National Cancer Institute. Childhood Cancer Data Initiative (CCDI). Accessed: July 12, 2024. Available from: https://www.cancer.gov/research/areas/childhood/childhood-cancer-data-initiative
Ref. 941. Georgetown University Health Policy Initiative. Millions of Children May Lose Medicaid: What Can Be Done to Help Prevent Them From Becoming Uninsured? Accessed: July 5, 2023. Available from: https://ccf.georgetown.edu/2022/02/17/millions-of-children-may-lose-medicaid-what-can-be-done-to-help-prevent-them-from-becoming-uninsured/
Ref. 942. Centers for Medicare & Medicaid Services. Streamlining the Medicaid, Children’s Health Insurance Program, and Basic Health Program Application, Eligibility Determination, Enrollment, and Renewal Processes Final Rule Fact Sheet. Accessed: July 12, 2024. Available from: https://www.cms.gov/newsroom/fact-sheets/streamlining-medicaid-childrens-health-insurance-program-and-basic-health-program-application
Ref. 943. National Institute of Minority Health and Health Disparities. Research Interest Areas. Accessed: March 17, 2024. Available from: https://www.ncbi.nlm.nih.gov/pubmed/
Ref. 944. National Cancer Institute. NCI Center to Reduce Cancer Health Disparities. Accessed: March 17, 2024. Available from: https://www.cancer.gov/about-nci/organization/crchd
Ref. 945. Centers for Disease Control and Prevention. What CDC Is Doing to Achieve Equity in Cancer Control. Accessed: March 17, 2024. Available from: https://www.cdc.gov/cancer/health-equity/what-cdc-is-doing/index.htm
Ref. 946. Centers for Disease Control and Prevention. Offering Flexible Hours and Locations | NBCCEDP. Accessed: July 12, 2024. Available from: https://www.cdc.gov/breast-cervical-cancer-screening/success/hours-locations.html
Ref. 947. Centers for Disease Control and Prevention. CDC’s CORE Commitment to Health Equity. Accessed: March 17, 2024. Available from: https://www.cdc.gov/health-equity/core/index.html
Ref. 948. Congress.gov. H.R.7585 – 117th Congress (2021-2022): Health Equity and Accountability Act of 2022. Accessed: July 12, 2024. Available from: https://www.congress.gov/bill/117th-congress/house-bill/7585
Ref. 949. The White House. FACT SHEET: Biden Cancer Moonshot Announces Commitments from Leading Health Insurers and Oncology Providers to Make Navigation Services Accessible to More than 150 Million Americans. Accessed: July 12, 2024. Available from: https://www.whitehouse.gov/ostp/news-updates/2024/03/08/fact-sheet-biden-cancer-moonshot-announces-commitments-from-leading-health-insurers-and-oncology-providers-to-make-navigation-services-accessible-to-more-than-150-million-americans/
Ref. 950. Inside Climate News. In Louisiana’s ‘Cancer Alley,’ Excitement Over New Emissions Rules Is Tempered By a Legal Challenge to Federal Environmental Justice Efforts – Inside Climate News. Accessed: July 12, 2024. Available from: https://insideclimatenews.org/news/10052024/louisiana-cancer-alley-emission-rules-environmental-justice/
Ref. 951. Collins MB, et al. (2016) Environ Res Lett, 11: 015004. DOI: 10.1088/1748-9326/11/1/015004.
Ref. 952. Johnston J, et al. (2020) Curr Environ Health Rep, 7: 48. DOI: 10.1007/s40572-020-00263-8.
Ref. 953. Keele University. Land of the Free? Environmental Racism and Its Impact on Cancer Alley, Louisiana. Accessed: Available from: https://www.keele.ac.uk/extinction/controversy/canceralley/
Ref. 954. James W, et al. (2012) Int J Environ Res Public Health, 9: 4365. DOI: 10.3390/ijerph9124365.
Ref. 955. ProPublica. EPA Calls Out Environmental Racism in Louisiana’s Cancer Alley. Accessed: July 12, 2024. Available from: https://www.propublica.org/article/cancer-alley-louisiana-epa-environmental-racism
Ref. 956. Human Rights Watch. US: Louisiana’s ‘Cancer Alley’. Dire Health Crisis From Government Failure to Rein in Fossil Fuels. Accessed: July 12, 2024. Available from: https://www.hrw.org/news/2024/01/25/us-louisianas-cancer-alley
Ref. 957. US Environmental Protection Agency. Environmental Justice. Accessed: March 17, 2024. Available from: https://www.epa.gov/environmentaljustice
Ref. 958. US Environmental Protection Agency. Air Data: Air Quality Data Collected at Outdoor Monitors Across the US. Accessed: July 12, 2024. Available from: https://www.epa.gov/outdoor-air-quality-data
Ref. 959. US Environmental Protection Agency. Biden-Harris Administration Finalizes Stronger Clean Air Standards for Chemical Plants, Lowering Cancer Risk and Advancing Environmental Justice. Accessed: July 12, 2024. Available from: https://www.epa.gov/newsreleases/biden-harris-administration-finalizes-stronger-clean-air-standards-chemical-plants
Ref. 960. Senate.gov. Booker, Grijalva, Lee, Duckworth Introduce the A. Donald McEachin Environmental Justice for All Act | U.S. Senator Cory Booker of New Jersey. Accessed: July 12, 2024. Available from: https://www.booker.senate.gov/news/press/booker-grijalva-lee-duckworth-introduce-the-a-donald-mceachin-environmental-justice-for-all-act
Ref. 961. US Food & Drug Administration. Modernization of Cosmetics Regulation Act of 2022 (MoCRA). Accessed: July 12, 2024. Available from: https://www.fda.gov/cosmetics/cosmetics-laws-regulations/modernization-cosmetics-regulation-act-2022-mocra
Ref. 962. Parikh RB, et al. (2022) J Natl Cancer Inst, 114: 1338. DOI: 10.1093/jnci/djac108.
Ref. 963. Bradley CJ, et al. (2022) J Natl Cancer Inst, 114: 1065. DOI: 10.1093/jnci/djac086.
Ref. 964. Federal Register. Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; Interoperability and Patient Access for Medicare Advantage Organization and Medicaid Managed Care Plans, State Medicaid Agencies, CHIP Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-Facilitated Exchanges, and Health Care Providers. Accessed: Jul 12, 2024. Available from: https://www.federalregister.gov/documents/2020/05/01/2020-05050/medicare-and-medicaid-programs-patient-protection-and-affordable-care-act-interoperability-and
Ref. 965. Federal Register. Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; Advancing Interoperability and Improving Prior Authorization Processes for Medicare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Children’s Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-Facilitated Exchanges, Merit-Based Incentive Payment System (MIPS) Eligible Clinicians, and Eligible Hospitals and Critical Access Hospitals in the Medicare Promoting Interoperability Program. Accessed: July 12, 2024. Available from: https://www.federalregister.gov/documents/2024/02/08/2024-00895/medicare-and-medicaid-programs-patient-protection-and-affordable-care-act-advancing-interoperability
